



(86) Date de dépôt PCT/PCT Filing Date: 2002/12/19
(87) Date publication PCT/PCT Publication Date: 2003/06/26
(45) Date de délivrance/Issue Date: 2012/05/08
(85) Entrée phase nationale/National Entry: 2004/07/22
(86) N° demande PCT/PCT Application No.: EP 2002/014577
(87) N° publication PCT/PCT Publication No.: 2003/051401
(30) Priorité/Priority: 2001/12/19 (DE101 62 480.8)


(51) Cl.Int./Int.Cl. *A61K 39/00* (2006.01),
A61K 38/19 (2006.01), *A61P 35/04* (2006.01)

(72) Inventeurs/Inventors:
HOERR, INGMAR, DE;
VON DER MULBE, FLORIAN, DE;
PASCOLO, STEVE, DE

(73) Propriétaire/Owner:
CUREVAC GMBH, DE

(74) Agent: KIRBY EADES GALE BAKER

(54) Titre : APPLICATION D'ARNM EN TANT QU'AGENT THERAPEUTIQUE POUR DES MALADIES TUMORALES
(54) Title: STABILISED MRNA TUMOUR VACCINE



(57) Abrégé/Abstract:

The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.



Abstract

5

The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a
10 tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against
15 cancer.

5

STABILIZED mRNA TUMOUR VACCINE

10

The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.

20

Gene therapy and genetic vaccination are molecular medicine methods which, when used in the therapy and prevention of diseases, will have considerable effects on medical practice. Both methods are based on the introduction of nucleic acids into cells or into tissues of the patient and on subsequent processing of the information coded by the nucleic acids introduced, i.e. expression of the desired polypeptides.

30

The conventional procedure of methods of gene therapy and of genetic vaccination to date is the use of DNA to insert the required genetic information into the cell. Various methods for introducing DNA into cells have been developed in this connection, such as e.g. calcium phosphate

transfection, polybrene transfection, protoplast fusion, electroporation, microinjection and lipofection, whereas lipofection in particular having emerged as a suitable method.

5

A further method which has been proposed in particular in the case of genetic vaccination methods is the use of DNA viruses as DNA vehicles. Such viruses have the advantage that because of their infectious properties a very high
10 transfection rate can be achieved. The viruses used are genetically modified, so that no functional infectious particles are formed in the transfected cell. In spite of this safety precaution, however, a certain risk of uncontrolled propagation of the genes having a gene therapy
15 action and the viral genes introduced cannot be ruled out because of possible recombination events.

The DNA introduced into the cell is conventionally integrated into the genome of the transfected cell to a
20 certain extent. On the one hand this phenomenon can exert a desired effect, since a long-lasting action of the DNA introduced can thereby be achieved. On the other hand, the integration into the genome results in a substantial risk of gene therapy. Thus e.g. the DNA introduced may be
25 inserted into an intact gene, which represents a mutation which interferes or even completely switches off the function of the endogenous gene. On the one hand enzyme systems which are essential for the cell may be switched off by such integration events, and on the other hand there
30 is also the danger of a transformation of the cell modified in this way into a degenerated state if a gene which is decisive for regulation of cell growth is modified by the

integration of the foreign DNA. A risk of the development of cancer therefore cannot be ruled out when using DNA viruses as gene therapeutics and vaccines. In this connection it is also to be noted that for effective
5 expression of the genes introduced into the cell, the corresponding DNA vehicles contain a strong promoter, e.g. the viral CMV promoter. Integration of such promoters into the genome of the treated cell can lead to undesirable changes in the regulation of gene expression in the cell.

10

A further disadvantage of the use of DNA as gene therapeutics and vaccines is the induction of pathogenic anti-DNA antibodies in the patient, causing a possibly fatal immune response.

15

In contrast to DNA, the use of RNA as a gene therapeutic or vaccine is to be classified as substantially safer. In particular, RNA does not involve the risk of being integrated into the genome of the transfected cell in a
20 stable manner. Furthermore, no viral sequences, such as promoters, are necessary for effective transcription. Moreover, RNA is degraded considerably more easily *in vivo*. Apparently because of the relatively short half-life of RNA in the blood circulation compared with DNA, no anti-RNA
25 antibodies have been detected to date. RNA can therefore be regarded as the molecule of choice for molecular medicine therapy methods.

Nevertheless, medical methods based on RNA expression
30 systems still require a solution to some fundamental problems before they are used more widely. One of the problems of using RNA is reliable cell- or tissue-specific

efficient transfer of the nucleic acid. Since RNA usually proves to be very unstable in solution, it has not hitherto been possible, or has been possible only in a very inefficient manner, to use RNA as a therapeutic or vaccine
5 by the conventional methods which are used with DNA.

RNA-degrading enzymes, so-called RNAases (ribonucleases), are responsible for the instability. Even the smallest impurities of ribonucleases are sufficient to degrade RNA
10 in solution completely. The natural degradation of mRNA in the cytoplasm of cells is very finely regulated. Several mechanisms are known in this respect. Thus, the terminal structure is of decisive importance for a functional mRNA. At the 5'-end is the so-called "cap structure" (a modified
15 guanosine nucleotide), and at the 3'-end a sequence of up to 200 adenosine nucleotides (the so-called poly-A tail). The RNA is recognized as mRNA and the degradation is regulated via these structures. Moreover, there are further processes which stabilize or destabilize RNA. Many of
20 these processes are still unknown, but an interaction between the RNA and proteins often appears to be decisive for this. For example, an "mRNA surveillance system" has recently been described (Hellerin and Parker, Annu. Rev. Genet. 1999, 33: 229 to 260), in which incomplete or
25 nonsense mRNA is recognized by certain feedback protein interactions in the cytosol and is rendered accessible to degradation, the majority of these processes being performed by exonucleases.

30 Some measures for increasing the stability of RNA and thereby rendering possible its use as a gene therapeutic or RNA vaccine have been proposed in the prior art.

To solve the abovementioned problems of the instability of RNA *ex vivo*, EP-A-1083232 proposes a process for introduction of RNA, in particular mRNA, into cells and organisms, in which the RNA is in the form of a complex with a cationic peptide or protein.

WO 99/14346 describes further processes for stabilizing mRNA. In particular, modifications of the mRNA which stabilize the mRNA species against the degradation by RNases are proposed. Such modifications concern on the one hand stabilization by sequence modifications, in particular reduction of the C and/or U content by base elimination or base substitution. On the other hand, chemical modifications, in particular the use of nucleotide analogues, and 5'- and 3'-blocking groups, an increased length of the poly-A tail and complexing of the mRNA with stabilizing agents and combinations of the measures mentioned, are proposed.

20

The US patents US 5,580,859 and US 6,214,804 disclose, *inter alia*, mRNA vaccines and therapeutics in the context of "transient gene therapy" (TGT). Various measures for increasing the translation efficiency and the mRNA stability based above all on untranslated sequence regions are described.

Bieler and Wagner (in: Schleef (ed.), *Plasmids for Therapy and Vaccination*, chapter 9, pages 147 to 168, Wiley-VCH, Weinheim, 2001) report on the use of synthetic genes in connection with gene therapy methods using DNA vaccines and lentiviral vectors. The construction of a synthetic *gag*

30

gene derived from HIV-1, in which the codons were modified (alternative codon usage) compared with the wild-type sequence such that they corresponded to the use of codons which are to be found in highly expressed mammalian genes, is described. By this means, the A/T content in particular was reduced compared with the wild-type sequence. The authors find in particular an increased expression rate of the synthetic gag gene in transfected cells. Furthermore, in mice an increased formation of antibodies against the gag protein was observed in mice immunized with the synthetic DNA construct, and also an increased cytokine release *in vitro* in transfected spleen cells of mice. Finally, an induction of a cytotoxic immune response was to be found in mice immunized with the gag expression plasmid. The authors of this article attribute the improved properties of their DNA vaccine substantially to a change, caused by the optimized codon usage, to the nucleocytoplasmic transporation of the mRNA expressed by the DNA vaccine. In contrast, the authors consider the effect of the modified codon usage on the translation efficiency to be low.

The present invention is therefore based on the object of providing a new system for gene therapy and genetic vaccination for tumours which overcomes the disadvantages associated with the properties of DNA therapeutics and vaccines.

This object is solved by the embodiments of the present invention characterized in the claims.

In one particular embodiment there is provided a process for the preparation of a pharmaceutical composition comprising the steps: (a) preparation of a part of a cDNA library from tumour tissue of a patient, wherein the part
5 is a subtraction library of the entire cDNA library and codes for tumour-specific antigens, the sequences of the tumour specific antigens are determined before step (a) and wherein the determination of the sequences of the tumour-specific antigens comprises an alignment with a cDNA
10 library from healthy tissue; (b) preparation of a matrix for *in vitro* transcription of mRNAs with the aid of the part of the cDNA library; and (c) *in vitro* transcribing of the matrix.

15 According to the invention, the expression "antigen from a tumour" means that the corresponding antigen is expressed in cells associated with a tumour. According to the invention, antigens from tumours are therefore in particular those which are produced in the degenerated
20 cells themselves. These are preferably antigens located on the surface of the cells. Furthermore, however, antigens from tumours are also those which are expressed in cells which are (were) not themselves (or originally themselves) degenerated but are associated with the tumour in question.

25 These also include e.g. antigens which are connected with tumour-supplying vessels or (re)formation thereof, in particular those antigens which are associated with neovascularization or angiogenesis, e.g. growth factors, such as VEGF, bFGF etc. Such antigens connected with a
30 tumour furthermore also include those from cells of the

7a

tissue embedding the tumour. Corresponding antigens of connective tissue cells, e.g. antigens of the extracellular matrix, are to be mentioned here.

- 5 According to the invention, in the pharmaceutical composition one (or more) mRNAs is used for therapy or inoculation, i.e. vaccination, for treatment or prevention (prophylaxis) of cancer diseases. The vaccination is based on the introduction of an antigen (or several antigens) of
10 a tumour, in the present case the genetic information for the antigen in the form of the mRNA which codes for the

antigen(s), into the organism, in particular into the cell. The mRNA contained in the pharmaceutical composition is translated into the (tumour) antigen, i.e. the polypeptide or antigenic peptide coded by the modified mRNA is
5 expressed, as a result of which an immune response directed against this polypeptide or antigenic polypeptide is stimulated. In the present case of the use as genetic vaccines for treatment of cancer, the immune response is therefore achieved by introduction of the genetic
10 information for antigens from a tumour, in particular proteins which are expressed exclusively on cancer cells, in that a pharmaceutical composition according to the invention which comprises an mRNA which codes for such a cancer antigen is administered. By this means, the cancer
15 antigen(s) is (are) expressed in the organism, as a result of which an immune response which is directed effectively against the cancer cells is provoked.

In its use as a vaccine, the pharmaceutical composition
20 according to the invention is to be considered in particular for treatment of cancer diseases (the mRNA preferably coding for a tumour-specific surface antigen (TSSA), e.g. for treatment of malignant melanoma, colon carcinoma, lymphomas, sarcomas, small-cell pulmonary
25 carcinoma, blastomas etc. Specific examples of tumour antigens are, inter alia, 707-AP, AFP, ART-4, BAGE, β -catenine/m, Bcr-abl, CAMEL, CAP-1, CASP-8, CDC27/m, CDK4/m, CEA, CT, Cyp-B, DAM, ELF2M, ETV6-AML1, G250, GAGE, GnT-V, Gp100, HAGE, HER-2/neu, HLA-A*0201-R170I, HPV-E7, HSP70-2M,
30 HAST-2, hTERT (or hTRT), iCE, KIAA0205, LAGE, LDLR/FUT, MAGE, MART-1/melan-A, MC1R, myosine/m, MUC1, MUM-1, -2, -3, NA88-A, NY-ESO-1, p190 minor bcr-abl, Pml/RAR α , PRAME, PSA,

PSM, RAGE, RU1 or RU2, SAGE, SART-1 or SART-3, TEL/AML1, TPI/m, TRP-1, TRP-2, TRP-2/INT2 and WT1.

According to a further preferred embodiment, the antigen(s)
5 from a tumour is or are a polyepitope of the antigen(s)
from a tumour. A "polyepitope" of an antigen or several
antigens is an amino acid sequence in which several or many
regions of the antigen(s) which interact with the antigen-
binding part of an antibody or with a T cell receptor are
10 represented. In this context, the polyepitope can be
complete and non-modified. However, according to the
present invention it can also be modified, in particular to
optimize the antibody/antigen and T cell receptor/antigen
interaction, respectively. A modification compared with the
15 wild-type polyepitope can include e.g. a deletion, addition
and/or substitution of one or more amino acid residues.
Accordingly, in the mRNA of the present invention which
codes for the modified polyepitope, one or more nucleotides
is/are removed, added and/or replaced, compared with the
20 mRNA which codes for the wild-type polyepitope.

In order to increase the stability of the (m)RNA contained
in the pharmaceutical composition of the present invention,
each (m)RNA contained in the pharmaceutical composition
25 preferably has one or more modifications, in particular
chemical modifications, which contribute towards increasing
the half-life of the (m)RNA (one or more) in the organism
or improve the transfer of the (m)RNA (one or more) into
the cell.

30

For example, in the sequences of eukaryotic mRNAs, there
are destabilizing sequence elements (DSE) to which signal

proteins bind and regulate the enzymatic degradation of the mRNA *in vivo*. For further stabilization of the modified mRNA preferably contained in the pharmaceutical composition according to the invention, where appropriate in the region
5 which codes for at least one antigen from a tumour one or more modifications compared with the corresponding region of the wild-type mRNA are carried out, so that no destabilizing sequence elements are present. According to the invention, it is of course also preferable, where
10 appropriate, to eliminate from the mRNA DSEs present in the untranslated regions (3'- and/or 5'-UTR).

Such destabilizing sequences are e.g. AU-rich sequences ("AURES"), which occur in 3'-UTR sections of numerous
15 unstable mRNAs (Caput et al., Proc. Natl. Acad. Sci. USA 1986, 83: 1670 to 1674). The RNA molecules contained in the pharmaceutical composition according to the invention are therefore preferably modified compared with the wild-type mRNA such that they contain no such destabilizing
20 sequences. This also applies to those sequence motifs which are recognized by possible endonucleases, e.g. the sequence GAACAAG, which is contained in the 3'-UTR segment of the gene which codes for the transferrin receptor (Binder et al., EMBO J. 1994, 13: 1969 to 1980). These sequence motifs
25 are also preferably eliminated in the modified mRNA of the pharmaceutical composition according to the invention.

A skilled person in the art is familiar with various processes which are suitable for substitution of codons in
30 the modified mRNA according to the invention. In the case of relatively short coding regions (which code for biologically active or antigenic peptides) e.g. the total

mRNA can be synthesized chemically using standard techniques.

Nevertheless, base substitutions are preferably introduced,
5 using a DNA matrix for the preparation of the modified mRNA
with the aid of techniques of the usual targeted
mutagenesis; Maniatis et al., Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Laboratory Press, 3rd
ed., Cold Spring Harbor, NY, 2001.

10

In this process, for the preparation of the mRNA, a
corresponding DNA molecule is therefore transcribed *in*
vitro. This DNA matrix has a suitable promoter, e.g. a T7
or SP6 promoter, for the *in vitro* transcription, which is
15 followed by the desired nucleotide sequence for the mRNA to
be prepared and a termination signal for the *in vitro*
transcription. According to the invention, the DNA molecule
which forms the matrix of the RNA construct to be prepared
is prepared by fermentative proliferation and subsequent
20 isolation as part of a plasmid which can be replicated in
bacteria. Plasmids which may be mentioned as suitable for
the present invention are e.g. the plasmids pT7TS (GenBank
Access Number U26404; Lai et al., Development 1995, 121:
2349 to 2360; cf. also fig. 8), pGEM[®] serie, e.g. pGEM[®]-1
25 (GenBank Access Number X65300; from Promega) and pSP64
(GenBank Access Number X65327); cf. also Mezei and Storts,
Purification of PCR Products, in: Griffin and Griffin
(ed.), PCR Technology: Current Innovation, CRC Press, Boca
Raton, FL, 2001.

30

Using short synthetic DNA oligonucleotides which contain
short single-stranded transitions at the cleavage sites

formed or genes prepared by chemical synthesis, the desired nucleotide sequence can thus be cloned into a suitable plasmid by molecular biology methods with which a skilled person in the art is familiar (cf. Maniatis et al., see
5 above). The DNA molecule is then excised the plasmid, in which it can be present in one or multiple copy, by digestion with restriction endonucleases.

The modified mRNA contained in the pharmaceutical
10 composition according to the invention can moreover have a 5'-cap structure (a modified guanosine nucleotide). Examples of cap structures which may be mentioned are m7G(5')ppp (5' (A,G(5')ppp(5')A and G(5')ppp(5')G.

15 According to a further preferred embodiment of the present invention, the modified mRNA contains a poly(A⁺) tail of at least about 25, in particular at least about 30, preferably at least about 50 nucleotides, more preferably at least about 70 nucleotides, particularly preferably at least
20 about 100 nucleotides. However, the poly(A⁺) tail can also comprise 200 and more nucleotides.

For efficient translation of the mRNA, effective binding of the ribosomes to the ribosome binding site (Kozak sequence:
25 GCCGCCACCAUGG, **AUG** forms the start codon) is necessary. In this respect, it has been found that an increased A/U content around this site renders possible a more efficient ribosome binding to the mRNA.

30 It is furthermore possible to insert one or more so-called IRES ("internal ribosomal entry site) into the mRNA. An IRES can thus function as the single ribosome binding site,

but it can also serve to provide an mRNA which codes several peptides or polypeptides which are to be translated by the ribosomes independently of one another ("multicistronic" or "polycistronic" mRNA). Examples of IRES sequences which can be used according to the invention are those from picornaviruses (e.g. FMDV), pestviruses (CFFV), polioviruses (PV), encephalomyocarditis viruses (ECMV), foot and mouth disease viruses (FMDV), hepatitis C viruses (HCV), classical swine fever viruses (CSFV), mouse leukoma virus (MLV), simian immunodeficiency viruses (SIV) or cricket paralysis viruses (CrPV).

According to a further preferred embodiment of the present invention, the mRNA has, in the 5'-and/or 3'-untranslated regions, stabilizing sequences which are capable of increasing the half-life of the mRNA in the cytosol.

These stabilizing sequences can have a 100 % sequence homology to naturally occurring sequences which occur in viruses, bacteria and eukaryotes, but can also be partly or completely of synthetic nature. Examples of stabilizing sequences which can be used in the present invention and which may be mentioned are the untranslated sequences (UTR) of the β -globin gene, e.g. from *Homo sapiens* or *Xenopus laevis*. Another example of a stabilizing sequence has the general formula (C/U)CCAN_xCCC(U/A)Py_xUC(C/U)CC, which is contained in the 3'-UTR of the very stable mRNA which codes for α -globin, α -(I)-collagen, 15-lipoxygenase or for tyrosine hydroxylase (cf. Holcik et al., Proc. Natl. Acad. Sci. USA 1997, 94: 2410 to 2414). Such stabilizing sequences can of course be used individually or in combination with one another and also in combination with

other stabilizing sequences known to a skilled person in the art.

For further stabilization of the mRNA, it is moreover
5 preferred to contain at least one analogue of naturally occurring nucleotides. This is based on the fact that the RNA-degrading enzymes occurring in the cells preferentially recognize naturally occurring nucleotides as a substrate. The degradation of RNA can therefore be made difficult by
10 insertion of nucleotide analogues, whereby the effect on the translation efficiency on insertion of these analogues, in particular in the coding region of the mRNA, can have a positive or negative effect on the translation efficiency.

15 In a list which is in no way conclusive, examples which may be mentioned of nucleotide analogues which can be used according to the invention are phosphoroamidates, phosphorothioates, peptide nucleotides, methylphosphonates, 7-deazaguanosine, 5-methylcytosine and inosine. The
20 preparation of such analogues is known to a skilled person in the art e.g. from the US patents 4,373,071, US 4,401,796, US 4,415,732, US 4,458,066, US 4,500,707, US 4,668,777, US 4,973,679, US 5,047,524, US 5,132,418, US 5,153,319, US 5,262,530 and 5,700,642. According to the
25 invention, such analogues can occur in untranslated and translated regions of the modified mRNA.

Furthermore, effective transfer of the preferably modified mRNA into the cells to be treated or the organism to be
30 treated can be improved if the mRNA is associated with a cationic or polycationic agent, in particular a corresponding peptide or protein, or bound thereto. The

mRNA is therefore present in the pharmaceutical composition according to the invention preferably in a form complexed or condensed with such an agent. In particular, the use of protamine as a polycationic, nucleic acid-binding protein is particularly effective in this context. The use of other cationic peptides or proteins, such as poly-L-lysine, poly-L-arginine or histones, is furthermore also possible. This procedure for stabilizing the modified mRNA is described in EP-A-1083232, the disclosure content of which in this respect is included in its full scope in the present invention.

The mRNA modified according to the invention can moreover also contain, in addition to the peptide or polypeptide which is antigenic or active in gene therapy, at least one further functional section which e.g. codes for a cytokine which promotes the immune response, (monokine, lymphokine, interleukin or chemokine, such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IFN- α , IFN- γ , GM-CFS, LT- α or growth factors, such as hGH).

The pharmaceutical composition according to the invention can further comprise one or more adjuvants to increase the immunogenicity. "Adjuvant" here is to be understood as meaning any chemical or biological compound which promotes a specific immune response. Various mechanisms are possible in this respect, depending on the various types of adjuvants used. For example, compounds which promote endocytosis of the modified mRNA contained in the pharmaceutical composition by dendritic cells (DC) form a first class of adjuvants which can be used. Other compounds which allow the maturation of the DC, e.g.

lipopolysaccharides, TNF- α or CD40 ligand, are a further class of suitable adjuvants. Generally, any agent which influences the immune system of the nature of a "warning signal" (LPS, GP96, oligonucleotides with the CpG motif) or
5 cytokines, in particular GM-CSF, can be used as an adjuvant which allow an immune response against an antigen which is coded by the modified mRNA to be increased and/or influenced in a targeted manner. In particular, the abovementioned cytokines are preferred in this context.

10 Further known adjuvants are aluminium hydroxide, Freund's adjuvant and the abovementioned stabilizing cationic peptides or polypeptides, such as protamine. Lipopeptides, such as Pam3Cys, are also particularly suitable for use as adjuvants in the pharmaceutical composition of the present
15 invention; c.f. Deres et al., Nature 1989, 342: 561-564.

Further particularly suitable adjuvants are moreover (other) RNA or also mRNA species, which can be added to the pharmaceutical composition of the present invention to
20 increase the immunogenicity. Such adjuvant RNA is advantageously chemically modified for stabilization ("cis modification" or "cis stabilization"), for example by the abovementioned nucleotide analogues, in particular phosphorothioate-modified nucleotides, or by the above
25 further measures for stabilization of RNA. A further advantageous possibility of stabilization is complexing or association ("trans association" or "trans modification" and "trans stabilization", respectively) with the abovementioned cationic or polycationic agents, e.g. with
30 protamine.

According to a further advantageous embodiment, the stability of the RNA molecules contained in the pharmaceutical composition (mRNA, coding for a tumour antigen, and optionally adjuvant (m)RNA) is increased by one or more RNase inhibitors. Preferred RNase inhibitors are peptides or proteins, in particular those from the placenta (e.g. from the human placenta) or pancreas. Such RNase inhibitors can also be in a recombinant form. A specific example of an RNase inhibitor is RNasin[®], which is commercially obtainable, e.g. from Promega. Such RNase inhibitors can be used generally for stabilizing RNA. A pharmaceutical composition comprising at least one RNA, in particular mRNA, which codes for at least one antigen, and at least one RNase inhibitor as defined above, optionally in combination with a pharmaceutically acceptable solvent, carrier and/or vehicle, is therefore also provided generally according to the invention. Corresponding antigens in a general form and solvents, carriers and vehicles are defined below. In respect of preferred tumour antigens, reference is made to the statements in this respect concerning the preferred pharmaceutical composition comprising at least one mRNA which codes for at least one antigen from a tumour.

The pharmaceutical composition according to the invention preferably comprises, in addition to the aqueous solvent and the mRNA, one or more further pharmaceutically acceptable carrier(s) and/or one or more further pharmaceutically acceptable vehicle(s). Corresponding routes for suitable formulation and preparation of the pharmaceutical composition according to the invention are disclosed in "Remington's Pharmaceutical Sciences" (Mack

Pub. Co., Easton, PA, 1980), which is a constituent in its full content of the disclosure of the present invention. Possible carrier substances for parenteral administration are e.g., in addition to sterile water or sterile saline solutions as aqueous solvents, also polyalkylene glycols, hydrogenated naphthalene and, in particular, biocompatible lactide polymers, lactide/glycolide copolymers or polyoxyethylene/polyoxypropylene copolymers. Compositions according to the invention can comprise filler substances or substances such as lactose, mannitol, substances for covalent linking of polymers, such as e.g. polyethylene glycol, to inhibitors according to the invention, complexing with metal ions or inclusion of materials in or on particular preparations of a polymer compound, such as e.g. polylactate, polyglycolic acid or hydrogel, or on liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte fragments or spheroplasts. The particular embodiments of the compositions are chosen according to the physical properties, for example in respect of solubility, stability, bioavailability or degradability. Controlled or constant release of the active compound component according to the invention in the composition includes formulations based on lipophilic depots (e.g. fatty acids, waxes or oils). Coatings of substances according to the invention or compositions comprising such substances, that is to say coatings with polymers (e.g. polyoxamers or polyoxamines) are also disclosed in the context of the present invention. Substances or compositions according to the invention can furthermore have protective coatings, e.g. protease inhibitors or permeability-increasing agents. Preferred aqueous carrier materials are e.g. water for

injection (WFI) or water buffered with phosphate, citrate or acetate etc., whereby the pH typically being adjusted to 5.0 to 8.0, preferably 6.0 to 7.0. The aqueous solvent or the further carrier(s) or the further vehicle(s) will
5 additionally preferably comprise salt constituents, e.g. sodium chloride, potassium chloride or other components which render the solution e.g. isotonic. Aqueous solvents or the further carrier(s) or the further vehicle(s) can furthermore comprise, in addition to the abovementioned
10 constituents, additional components, such as human serum albumin (HSA), Polysorbate 80, sugars or amino acids.

The method and mode of administration and the dosage of the pharmaceutical composition according to the invention
15 depend on the disease to be treated and the stage of advancement thereof, and also the body weight, the age and the sex of the patient.

The concentration of the modified mRNA in such formulations
20 can therefore vary within a wide range from 1 µg to 100 mg/ml. The pharmaceutical composition according to the invention is preferably administered to the patient parenterally, e.g. intravenously, intraarterially, subcutaneously or intramuscularly. It is also possible to
25 administer the pharmaceutical composition topically or orally. The pharmaceutical composition according to the invention is preferably administered intradermally. A transdermal administration with the aid of electric currents or by osmotic forces is furthermore possible. The
30 pharmaceutical composition of the present invention can moreover be injected locally into a tumour.

Thus, a method for treatment or a vaccination method for prevention of cancer diseases or the abovementioned diseases which comprises administration of the pharmaceutical composition according to the invention to a patient, in particular a human, is thus also provided according to the invention.

According to a preferred embodiment of the treatment or vaccination method or in the use, defined above, of the mRNA according to the invention which codes for at least one antigen from a tumour for the preparation of a pharmaceutical composition for treatment and/or prevention of cancer diseases one or more cytokine(s) is administered to the patient, in addition to the pharmaceutical composition according to the invention.

A treatment or vaccination method comprising administration of at least one RNA, preferably mRNA, which code(s) for at least one antigen from a tumour (in accordance with the above definition) and is (are) optionally stabilized in accordance with the above statements, and at least one cytokine, e.g. one or more of the abovementioned cytokines, in particular GM-CSF, to a patient, in particular a human, is therefore also provided generally according to the invention. The method is used in particular for treatment and/or prevention of corresponding cancer diseases (e.g. the above cancer diseases). The present invention is accordingly also directed generally to a pharmaceutical composition comprising at least one RNA, preferably mRNA, which code(s) for at least one antigen from a tumour (according to the above definition) and is (are) optionally stabilized in accordance with the above statements, and at

least one cytokine, e.g. one or more of the abovementioned cytokines, such as GM-CSF, preferably in combination with a pharmaceutically acceptable carrier and/or vehicle, e.g. an aqueous solvent, or one or more of the carriers, solvents
5 or vehicles defined above. The use of cytokines, e.g. one or more of the abovementioned cytokines, in particular GM-CSF, in combination with one or more RNA molecule(s) as defined above, for treatment and/or prevention of cancer diseases (e.g. cancer diseases listed above) is thus also
10 disclosed according to the invention.

According to a further preferred embodiment of the present invention, the cytokine, e.g. GM-CSF, is administered simultaneously with or, which is more preferable, before or
15 after the pharmaceutical composition comprising the mRNA which codes for at least one antigen from a tumour (or is used for the preparation of a corresponding medicament for simultaneous administration with or for administration before or after the abovementioned (m)RNA). The
20 administration of the cytokine, in particular GM-CSF, is very particularly preferably carried out shortly before (e.g. about 15 min or less, e.g. about 10 or about 5 min) or a relatively short time (e.g. about 5, 10, 15, 30, 45 or 60 min) after or a longer time (e.g. about 2, 6, 12, 24
25 or 36 h) after the administration of the pharmaceutical composition defined above or generally after the (m)RNA of at least one which codes for at least one antigen from a tumour.

30 The application of the cytokine, e.g. GM-CSF, can be carried out in this context by the same route as the pharmaceutical composition according to the invention or

the at least one (m)RNA which codes for at least one antigen from a tumour or in a manner separate from this. Suitable administration routes and also the suitable formulation possibilities in respect of the cytokine(s) can
5 be found from the above statements in respect of the pharmaceutical compositions according to the invention. In the case of a human patient, a GM-CSF dose of 100 micrograms/m² in particular is advisable. The administration of the cytokine, e.g. GM-CSF, is
10 particularly preferably carried out by an s.c. injection.

The pharmaceutical compositions of the present invention or the RNA which codes for an antigen from a tumour and where appropriate, in association therewith, the cytokine(s) are
15 preferably administered in the form of interval doses. For example, a dose of a pharmaceutical composition according to the invention can be administered in relatively short intervals, e.g. daily, every second day, every third day etc., or, which is more preferable, in longer intervals,
20 e.g. once weekly, once in two weeks, once in three weeks, once a month etc. The intervals can also be changeable in this context, whereby it being necessary in particular to take into account the immunological parameters of the patient. For example, the administration of a
25 pharmaceutical composition according to the invention (and where appropriate, in association therewith, also the administration of the cytokine(s)) can follow a treatment plan in which the interval is shorter, e.g. once in two weeks, at the start of the treatment and then, depending on
30 the course of treatment or the appropriately determined immunological parameters of the patient, the interval is lengthened to e.g. once a month. A therapy plan tailor-made

to the particular individual can thus be applied according to the patient, in particular his condition and his immunological parameters.

5 The present invention also provides a process for the preparation of the pharmaceutical composition defined above, comprising the steps:

- (a) preparation of a cDNA library, or a part thereof, from tumour tissue of a patient,
- 10 (b) preparation of a matrix for *in vitro* transcription of RNA with the aid of the cDNA library or a part thereof and
- (c) *in vitro* transcribing of the matrix.

15 The tumour tissue of the patient can be obtained e.g. by a simple biopsy. However, it can also be provided by surgical removal of tumour-invaded tissue. The preparation of the cDNA library or a part thereof according to step (a) of the preparation process of the present invention can moreover
20 be carried out after the corresponding tissue has been deep-frozen for storage, preferably at temperatures below -70°C. For preparation of the cDNA library or a part thereof, isolation of the total RNA, e.g. from a tumour tissue biopsy, is first carried out. Processes for this are
25 described e.g. in Maniatis et al., *supra*. Corresponding kits are furthermore commercially obtainable for this, e.g. from Roche AG (e.g. the product "High Pure RNA Isolation Kit"). The corresponding poly(A⁺) RNA is isolated from the total RNA in accordance with processes known to a person
30 skilled in the art (cf. e.g. Maniatis et al., *supra*).
Appropriate kits are also commercially obtainable for this. An example is the "High Pure RNA Tissue Kit" from Roche AG.

Starting from the poly(A⁺) RNA obtained in this way, the cDNA library is then prepared (in this context cf. also e.g. Maniatis et al., *supra*). For this step in the preparation of the cDNA library also, commercially obtainable kits are available to a person skilled in the art, e.g. the "SMART PCR cDNA Synthesis Kit" from Clontech Inc. The individual sub-steps from the poly(A⁺) RNA to the double-stranded cDNA is shown schematically in fig. 11 by the example of the process in accordance with the "SMART PCR cDNA Synthesis Kit" from Clontech Inc.

According to step (b) of the above preparation process, starting from the cDNA library (or a part thereof), a matrix is synthesized for the *in vitro* transcription. According to the invention, this is effected in particular by cloning the cDNA fragments obtained into a suitable RNA production vector. The suitable DNA matrix and the plasmids which are preferred according to the invention are already mentioned above in connection with the preparation of the mRNA for the pharmaceutical composition according to the invention.

For *in vitro* transcription of the matrix prepared in step (b) according to the invention, these are first linearized with a corresponding restriction enzyme, if they are present as circular plasmid (c)DNA. Preferably, the construct cleaved in this way is purified once more, e.g. by appropriate phenol/chloroform and/or chloroform/phenol/isoamyl alcohol mixtures, before the actual *in vitro* transcription. By this means it is ensured in particular that the DNA matrix is in a protein-free form. The enzymatic synthesis of the RNA is then carried

out starting from the purified matrix. This sub-step takes place in an appropriate reaction mixture comprising the linearized, protein-free DNA matrix in a suitable buffer, to which a ribonuclease inhibitor is preferably added, using a mixture of the required ribonucleotide triphosphates (rATP, rCTP, rUTP and rGTP) and a sufficient amount of a RNA polymerase, e.g. T7 polymerase. The reaction mixture is present here in RNase-free water. Preferably, a CAP analogue is also added during the actual enzymatic synthesis of the RNA. After an incubation of an appropriately long period, e.g. 2 h, at 37 °C, the DNA matrix is degraded by addition of RNase-free DNase, incubation preferably being carried out again at 37 °C.

Preferably, the RNA prepared in this way is precipitated by means of ammonium acetate/ethanol and, where appropriate, washed once or several times with RNase-free ethanol. Finally, the RNA purified in this way is dried and, according to a preferred embodiment, is taken up in RNase-free water. The RNA prepared in this way can moreover be subjected to several extractions with phenol/chloroform or phenol/chloroform/isoamyl alcohol.

According to a further preferred embodiment of the preparation process defined above, only a part of a total cDNA library is obtained and converted into corresponding mRNA molecules. According to the invention, a so-called subtraction library can therefore also be used as part of the total cDNA library in order to provide the mRNA molecules according to the invention. A preferred part of the cDNA library of the tumour tissue codes for the tumour-specific antigens. For certain tumours, the corresponding

antigens are known. According to a further preferred embodiment, the part of the cDNA library which codes for the tumour-specific antigens can first be defined (i.e. before step (a) of the process defined above). This is
5 preferably effected by determining the sequences of the tumour-specific antigens by an alignment with a corresponding cDNA library from healthy tissue.

The alignment according to the invention comprises in
10 particular a comparison of the expression pattern of the healthy tissue with that of the tumour tissue in question. Corresponding expression patterns can be determined at the nucleic acid level e.g. with the aid of suitable hybridization experiments. For this e.g. the corresponding
15 (m)RNA or cDNA libraries of the tissue can in each case be separated in suitable agarose or polyacrylamide gels, transferred to membranes and hybridized with corresponding nucleic acid probes, preferably oligonucleotide probes, which represent the particular genes (northern and southern
20 blots, respectively). A comparison of the corresponding hybridizations thus provides those genes which are expressed either exclusively by the tumour tissue or to a greater extent therein.

25 According to a further preferred embodiment, the hybridization experiments mentioned are carried out with the aid of a diagnosis by microarrays (one or more microarrays). A corresponding DNA microarray comprises a defined arrangement, in particular in a small or very small
30 space, of nucleic acid, in particular oligonucleotide, probes, each probe representing e.g. in each case a gene, the presence or absence of which is to be investigated in

the corresponding (m)RNA or cDNA library. In an appropriate microarrangement, hundreds, thousands and even tens to hundreds of thousands of genes can be represented in this way. For analysis of the expression pattern of the particular tissue, either the poly(A⁺) RNA or, which is preferable, the corresponding cDNA is then marked with a suitable marker, in particular fluorescence markers are used for this purpose, and brought into contact with the microarray under suitable hybridization conditions. If a cDNA species binds to a probe molecule present on the microarray, in particular an oligonucleotide probe molecule, a more or less pronounced fluorescence signal, which can be measured with a suitable detection apparatus, e.g. an appropriately designed fluorescence spectrometer, is accordingly observed. The more the cDNA (or RNA) species is represented in the library, the greater will be the signal, e.g. the fluorescence signal. The corresponding microarray hybridization experiment (or several or many of these) is (are) carried out separately for the tumour tissue and the healthy tissue. The genes expressed exclusively or to an increased extent by the tumour tissue can therefore be concluded from the difference between the signals read from the microarray experiments. Such DNA microarray analyses are described e.g. in Schena (2002), Microarray Analysis, ISBN 0-471-41443-3, John Wiley & Sons, Inc., New York, the disclosure content in this respect of this document being included in its full scope in the present invention.

However, the establishing of tumour tissue-specific expression patterns is in no way limited to analyses at the nucleic acid level. Methods known from the prior art which

serve for expression analysis at the protein level are of course also familiar to a person skilled in the art. There may be mentioned here in particular techniques of 2D gel electrophoresis and mass spectrometry, whereby these techniques advantageously also can be combined with protein biochips (i.e., microarrays at the protein level, in which e.g. a protein extract from healthy or tumour tissue is brought into contact with antibodies and/or peptides applied to the microarray substrate). With regard to the mass spectroscopy methods, MALDI-TOF ("matrix assisted laser desorption/ionization-time of flight") methods are to be mentioned in this respect. The techniques mentioned for protein chemistry analysis to obtain the expression pattern of tumour tissue in comparison with healthy tissue are described e.g. in Rehm (2000) *Der Experimentator: Proteinbiochemie/Proteomics [The Experimenter: Protein Biochemistry/Proteomics]*, Spektrum Akademischer Verlag, Heidelberg, 3rd ed., to the disclosure content of which in this respect reference is expressly made *expressis verbis* in the present invention. With regard to protein microarrays, reference is moreover again made to the statements in this respect in Schena (2002), *supra*.

The figures show:

25

Fig. 1 shows a graphical view of the results of a tumour vaccination, with RNA, of mice (rat Her-2/neu transgenic animals) which develop mammary carcinomas spontaneously. The tumour multiplicity is plotted on the y-axis against the age of the mice on the x-axis. Untreated mice (n = 4), which served as a control, all had tumours at an age of 6

30

months. Three mice were injected with DNA which codes for Her-2/neu, one mouse being tumour-free after 10 months. As a further negative control, 4 mice received an antisense mRNA complementary to the mRNA for Her-2/neu. These mice also all had tumours after 6 months (not shown). In contrast, one of 4 mice which were injected with mRNA which codes for Her-2/neu (i.e., the sense strand) was tumour-free after 9 months.

10

Fig. 2 shows a graphical view of the results of experiments relating to beta-galactosidase (beta-Gal)-specific CTL (cytotoxic T lymphocyte) activity by immunization with an mRNA which codes for beta-Gal, under the influence of GM-CSF. BALB/c mice were immunized with 25 µg of mRNA which codes for beta-Gal by injection into the inner auricula. The splenocytes were stimulated with beta-Gal protein *in vitro* and the CTL activity was determined 6 days after the *in vitro* stimulation using a standard ⁵¹Cr release test. The target cells were P815 (H₂^d) cells which were charged (■) with the synthetic peptide TPHPARIGL, which corresponds to the H₂^d epitope of beta-Gal, or were not charged (▲). In each case three or two animals were treated per group. Animals which were injected i.d. in both auriculae with only injection buffer served as a negative control. Animals which were injected i.d. in both auriculae with 10 µg of a plasmid which codes for beta-Gal in PBS served as a positive control ("DNA"). The test groups received RNA which codes for beta-Gal by itself or in combination with

15

20

25

30

GM-CSF, which was injected 24 h ("GM-CSF t-1"), 2 h before the RNA injection ("GM-CSF t0") or 24 h after the RNA injection ("GM-CSF t+1") into the same site (into the auriculae) or at another site (s.c. on the back). In each case three different effector/target cell ratios (200, 44, 10) were tested.

Fig. 3 shows further graphical views of the results of ELISA standard tests specific for IFN-gamma (A) and IL-4 (B), which document the corresponding cytokine production of splenocytes which were restimulated with beta-Gal protein *in vitro*. BALB/c mice were immunized as already described above for fig. 2. The splenocytes were stimulated with beta-Gal protein *in vitro*, the corresponding culture supernatants were obtained and the IFN-gamma or IL-4 concentration was determined using an ELISA standard test.

20

Fig. 4 shows further graphical views which demonstrate the antibody response of mice immunized according to the invention. BALB/c mice were immunized as described for fig. 2. Two weeks after the boost, blood was taken and the blood serum was obtained therefrom. Beta-Gal-specific IgG1 (A) and IgG2a antibodies (B) were determined with the aid of an ELISA test. In each case the extinction (OD) at 405 nm which results from the conversion of the substrate ABTS in the ELISA test is shown on the y-axis. The extinctions shown are the values from

30

which the corresponding values of mice treated with injection buffer are subtracted.

Fig. 5 shows microscope sections, stained with X-Gal, of the auricula of mice which have been injected i.d. into the auricula with mRNA which codes for beta-galactosidase. 12 hours after the injection of 25 µg RNA in HEPES-NaCl injection buffer, the ears were removed and sections stained with X-Gal were prepared. Blue cells indicate a beta-galactosidase activity. As can be seen from the two sections, only few blue cells are present.

Fig. 6 shows a section, corresponding to fig. 5, through an auricula of a mouse which was injected into the auricula with mRNA which codes for beta-galactosidase and was stabilized with protamine. The microscope section stained with X-Gal show a few cells stained blue.

Fig. 7 shows two further sections through the auricula of mice, two images being produced per section in order to represent a larger area. In this case, mRNA which codes for beta-galactosidase, in a buffer, to which 10 U RNasin, an enzymatic RNase inhibitor from the pancreas (obtainable from Roche or Promega) was added directly before the injection, was injected into the auricula. Compared with the sections of fig. 5 and fig. 6, significantly more blue-stained regions of cells with beta-galactosidase activity are to be recognized.

Fig. 8 shows a schematical view of the plasmid pT7TS, which was used for the *in vitro* transcription. Constructs according to the invention were cloned into the BglII and SpeI sites, the relative position of which to one another is shown. The region shaded in black contains the 5' untranslated region of the beta-globin gene from *Xenopus laevis*, while the region shaded in grey represents a corresponding 3' untranslated region of the beta-globin gene from *X. laevis*. The relative position of the T7 promoter, the PstI site used for sequencing, the poly(A⁺) tail (A₃₀C₃₀) and, with an arrow, the transcription direction are furthermore indicated.

Fig. 9 shows in a flow chart, by way of example, the course of an RNA vaccination therapy according to the invention with assisting administration of GM-CSF. The mRNA molecules which code for one or more tumour antigens (MUC1, Her-2/neu, telomerase, MAGE-1) or a mRNA which codes for a control antigen (influenza matrix protein (IMP), a viral antigen) are administered i.d. to the patient on days 0, 14, 28 and 42. In addition, one day after the RNA inoculation the patient is injected s.c. with GM-CSF (Leucomax[®] (100 µg/m²) from Novartis/Essex Pharma). When the course is stable or there is an objective tumour response (complete remission (CR) or partial remission (PR)), the patients receive the vaccinations s.c. once a month. After the fourth injection (day 49), the response of the

tumour is evaluated radiologically, by laboratory chemistry or sonographically, and the immunological phenomena induced by the therapy are evaluated. From day 70, the immunization therapy is continued at intervals of 4 weeks. On day 0, 14, 28, 42 and 49, blood samples are taken for determination of appropriate laboratory parameters, the differential blood count (Diff-BB), FACS analysis and cytokines. Restaging of the patient takes place from day 49 and where appropriate every further 4 to 8 weeks.

Fig. 10 shows a flow chart of the construction of autologous, stabilized RNA according to the preparation process of the present invention. Tumour tissue is first obtained, e.g. by biopsy. The total RNA is extracted from this. A cDNA library is constructed with the aid of the poly(A⁺) RNA obtained from the RNA extraction. Starting from this, after preparation of a corresponding DNA matrix, the autologous, stabilized RNA is obtained by means of *in vitro* transcription.

Fig. 11 shows a reaction scheme of the steps for preparation of a cDNA library, starting from poly(A⁺) RNA, for the SMART PCR cDNA Synthesis Kit from Clontech Inc. by way of example.

Fig. 12 shows a photograph of an agarose gel which shows the typical size fractionation of a cDNA library compiled from human placenta tissue. A length marker with fragments of the length shown on the left is plotted in track M. The "DS cDNA" track

contains the cDNA library. Those fragments which correspond to the expected size fraction (about 200 bp to 4,000 bp) are used for the *in vitro* transcription.

5

Fig. 13 shows by way of example a treatment plan for the tumour therapy according to the invention by injection of a tumour mRNA library, here in combination with GM-CSF, for patients with malignant melanoma. Autologous, stabilized RNA prepared from the patient's own tumour tissue is used for this. This amplified autologous tumour RNA is administered to the patient i.d. on days 0, 14, 28 and 42. In addition, one day after the RNA injection the patient is injected s.c. with GM-CSF (Leucomax® 100 µg/m² Novartis/Essex Pharma). Two weeks after the fourth injection (day 56), the response of the tumour is evaluated by a staging analysis (inter alia sonography, thorax X-ray, CT etc.) and by assessment of the immunological parameters induced by the therapy. When the course of the disease is stable or there is an objective tumour response (CR or PR), the patient receives in each case a further vaccination every four weeks. Further restaging analyses are carried out on day 126 and then at intervals of 12 weeks.

15

20

25

30

Fig. 14 shows once more schematically of the general course of a therapy with the pharmaceutical composition according to the invention with autologous, amplified tumour RNA, i.e. the RNA contained in the pharmaceutical composition represents a cDNA

library of the tumour tissue. A sample of the
tumour tissue is first obtained, e.g. via a biopsy.
The total and then the poly(A⁺) RNA are prepared
from the tissue by appropriate extractions.
5 Starting from the poly(A⁺) RNA, a cDNA library is
constructed and is cloned into a vector suitable
for subsequent *in vitro* transcription. An RNA
vaccine is then obtained by *in vitro* transcription,
and is injected into the patient from whom the
10 tumour tissue has been taken to combat the tumour.

The following embodiment examples explain the present
invention in more detail, without limiting it.

15 **EXAMPLES**

Example 1: Tumour vaccination with RNA in an animal model

Materials and methods

20

Capped mRNA which codes for a shortened version of the Her-
2/neu protein of the rat ("ECD-TM-neu-rat", containing the
extracellular domain and the transmembrane region, but not
the cytoplasmic region) was prepared, using the "SP6
25 mMessengerMachine" (Ambion), with the aid of a plasmid which
substantially corresponded to the structure shown in
fig. 8, but contained an SP6 promoter instead of the T7
promoter and in which the ECD-TM-neu-rat construct was
inserted after the SP6 RNA polymerase promoter. The mRNA
30 prepared was dissolved in injection buffer (150 mM NaCl,
10 mM HEPES) at a concentration of 0.8 mg/l and the
solution was mixed with protamine sulfate (Sigma) (1 mg

protamine per 1 mg RNA). 50 µl of this solution were injected into the auriculae (in each case 25 µl per ear) of mice. Eight injections were performed, in each case one at the age of 6, 8, 13, 15, 20, 22, 27 and 29 weeks. Mice to which corresponding injections with injection buffer, with plasmid DNA which codes for ECD-TM-neu rat or with an antisense mRNA corresponding to the mRNA according to the invention were administered served as controls.

10 Results

Female BalB-neu T mice (BalB/c mice which express the oncogene Her-2/neu of the rat; cf. Rovero et al. (2000) J. Immunol. 165(9):5133-5142) which develop mammary carcinomas spontaneously were immunized with RNA which codes for a shortened version of the Her-2/neu protein ("ECD-TM-neu-rat", containing the extracellular domains and the transmembrane region, but not the cytoplasmic region). Four mice treated with injection buffer served as a negative control. A further group of three mice was injected with DNA which codes for the shortened Her-2/neu. Four mice received the mRNA which codes, according to the invention, for the tumour antigen Her-2/neu (shortened version of ECD-TM, see above). Four mice which were injected with the corresponding antisense RNA served as a further control group. As shown in fig. 1, in the animals of the untreated control group a tumour multiplicity of on average 10 was observed after 26 weeks, whereby all animals having palpable breast tumours at the age of about 20 weeks. In contrast, in the case of immunization with the mRNA which codes for ECD-TM-neu-rat, a significant slowing down of the formation of carcinomas is to be observed, in particular a

tumour multiplicity of 10 is achieved only at the age of 30 weeks. Furthermore, the size of the tumours is also reduced (not shown). Of the 4 mice treated with the mRNA according to the invention, one was still tumour-free after 9 months.

5 That group of mice which had been injected with the antisense mRNA all showed tumours at the age of 6 months. The comparison group of mice injected with plasmid DNA which codes for the shortened version of Her-2/neu also showed a carcinoma formation which was slowed down compared

10 with the untreated control group (cf. also in respect of corresponding plasmid DNA experiments on intramuscular injection: Di Carlo et al. (2001) Clin. Cancer Res. 7 (3rd supplement): 830s-837s), but the formation of carcinomas up to the 27th week was not slowed down to the same extent as

15 in the case of immunization with mRNA according to the invention which codes for the shortened version of Her-2/neu. Furthermore, in the case of immunization with DNA, the abovementioned disadvantages, in particular the risk of integration of the DNA into the genome, the formation of

20 anti-DNA antibodies etc., are to be taken into account.

Example 2: Influence of GM-CSF on RNA vaccination

Materials and methods

25

Mice

BALB-c AnNCr1BR (H-2^d) mice (female) 6-10 weeks old were obtained from Charles River (Sulzfeld, Germany).

30

Plasmids and preparation of RNA

The ORF (LacZ) which codes for beta-galactosidase, flanked by 5'-and 3'-untranslated sequences from the beta-globin gene of *X. Laevis*, was into the plasmid pT7TS (P.A. Creek, Austin, TX, USA), in order to prepare the plasmid pT7TS-kozak-5' beta gl-lacZ-3' beta gl-A30C30 (cf. Hoerr et al. (2000) Eur. J. Immunol. 30: 1-7). A schematical view of the general structure of the plasmid pT7TS with the flanking 5' and 3' untranslated sequences from the beta-globin gene of *X. Laevis* is shown in fig. 8.

The plasmid prepared in this way was linearized with PstI and transcribed *in vitro* using the m-MessagemMachineT7 Kit (Ambion, Austin, TX USA). The RNA prepared in this way was purified by means of LiCl precipitation, phenol/chloroform extraction and ammonium acetate precipitation. Finally, the purified RNA was resuspended in injection buffer (150 mM NaCl, 10 mM HEPES) in a concentration of 0.5 mg/ml.

20

Media and cell culture

P815 and P13.1 cells were cultured in RPMI 1640 (Bio-Whittaker, Verviers, Belgium), supplemented with 10% heat-inactivated foetal calf serum (FCS) (PAN systems, Germany), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin.

CTL cultures were kept in RPMI 1640 medium, supplemented with 10 % FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 0.05 μ M beta-mercaptoethanol, 50 mg/ml gentamycin, MEM non-essential amino acids (100 x)

and 1 mM sodium pyruvate. The CTL were restimulated for one week with 1 mg/ml beta-galactosidase protein (Sigma, Taufkirchen, Germany). On day 4, 4 ml of culture supernatant were carefully pipetted off and replaced by
5 fresh medium containing 10 U/ml rIL-2 (final concentration).

Immunization

10 3 BALB/c mice per group were anesthetized with 20 mg pentobarbital i.p. per mouse. The mice were then injected i.d. in both auriculae with 25 mg of mRNA which codes for beta-galactosidase (beta-Gal) in injection buffer (150 mM NaCl, 10 mM HEPES). In some cases, granulocyte macrophage
15 colony-stimulating factor (GM-CSF) was additionally injected into the same site or into an injection site away from this (into the auricula or s.c. into the back) 24 h or 2 h before or 24 h after the RNA injection. As a positive control, animals were injected i.d. in both auriculae with
20 in each case 10 mg of a DNA plasmid which codes for beta-gal in PBS. A group of animals to which only injection buffer was administered i.d. into both auriculae served as a negative control. Two weeks after the first injection, a boost injection was performed in each case in the same
25 manner as the first injection. Two weeks after the boost injection, blood was taken, the mice were sacrificed and the spleen was removed.

⁵¹Cr release test

30

Splenocytes obtained from the spleen were stimulated with beta-gal protein *in vitro* and the CTL activity was

determined after 6 days using a 6-hours ^{51}Cr standard test as described in Rammensee et al. (1989) Immunogenetics 30: 296 - 302. Summarized briefly, target cells were marked with ^{51}Cr and charged with the peptide TPHPARIGL for 20 min at room temperature. After co-incubation of effector and target cells (at in each case three different ratios of effector:target cells: 200, 44 and 10) in circular plates with 96 wells for 6 h, 50 ml of 200 ml of culture supernatant were pipetted into a Luma scintillation plate (Packard) with 96 wells and, after drying, the radioactivity was measured with a scintillation counter (1405 Microbeta Plus). The percentage specific release was determined from the amount of ^{51}Cr released into the medium (A) minus the spontaneous release (B) divided by the total release (C) (using Triton X-100) minus the spontaneous release (B): Per cent specific lysis = $100 (A-B)/(C-B)$.

Cytokine ELISA

After 4 days of restimulation with beta-gal protein, the supernatant of the splenocyte culture was pipetted off and stored at $-50\text{ }^{\circ}\text{C}$ until used. 100 ml anti-mouse-anti-IFN-gamma or -IL-4 scavenger antibodies (Becton Dickenson, Heidelberg, Germany) were pipetted out overnight at $4\text{ }^{\circ}\text{C}$ on MaxiSorb plates (Nalge Nunc International, Nalge, Denmark) at a concentration of 1 mg/ml in coating buffer (0.02 % NaN_3 , 15 mM Na_2CO_3 , 15 mM NaHCO_3 , pH 9.6). After washing three times with washing buffer (0.05 % Tween 20 in PBS), the plates were saturated with 200 ml of blocking buffer (0.05 % Tween 20, 1 % BSA in PBS) for 2 h at $37\text{ }^{\circ}\text{C}$. After washing three times with washing buffer, 100 ml of the cell culture supernatants were incubated for 5 h at $37\text{ }^{\circ}\text{C}$. The

plates were then washed four times with washing buffer, 100 ml of biotinylated anti-mouse-anti-IFN-gamma or -IL-4 detection antibodies (Becton Dickenson, Heidelberg, Germany) per well at a concentration of 0.5 mg/ml in blocking buffer were pipetted and incubation was carried out for 1 h at room temperature. After washing three times with washing buffer, 100 ml of a 1/1,000 dilution of streptavidin-HRP (BD Biosciences, Heidelberg, Germany) were added into each well. After 30 min at room temperature, the plates were washed three times with washing buffer and twice with bidistilled water. Thereafter, 100 ml of the ABTS substrate were added into each well. After 30 min at room temperature, the extinction at 405 nm was measured with a Sunrise ELISA reader (Tecan, Crailsheim, Germany).

Antibody ELISA

Two weeks after the boost injection, blood was taken from the mice via the orbital vein and blood serum was prepared. 100 ml of beta-gal protein at a concentration of 100 mg/ml in coating buffer (0.05 M Tris-HCl, 0.15 M NaCl, 5 mM CaCl₂, pH 7.5) were pipetted out for 2 h at 37 °C on to MaxiSorb plates (Nalge Nunc International, Nalge, Denmark). The plates were then washed three times with 200 ml of washing buffer (0.05 M Tris-HCl, 0.15 M NaCl, 0.01 M EDTA, 0.1 % Tween 20, 1 % BSA, pH 7.4) and saturated with protein with 200 ml of washing buffer overnight at 4 °C. The plates were washed three times with washing buffer and blood sera were added in a dilution of 1/10, 1/30 or 1/90 in washing buffer. After 1 h at 37 °C, the plates were washed three times with washing buffer and 100 ml of 1/1,000 dilutions

of goat anti-mouse IgG1 or IgG2a antibodies (Caltag, Burlington, CA, USA) were added. After 1 h at room temperature, the wells were washed three times with washing buffer and 100 µl of ABTS substrate per well were added. After 15 - 30 min at room temperature, the extinction at 405 nm was measured with a Sunrise ELISA reader (Tecan, Crailsheim, Germany).

Results and discussion

10

It was confirmed that direct injection of RNA which codes for beta-galactosidase into the auricula of mice induces an anti-beta-galactosidase immune response, substantially of the Th2 type. Production of anti-beta-galactosidase immunoglobulins of the IgG1 type (fig. 3A) and secretion of IL-4 (fig. 3B) was found in splenocytes, stimulated with beta-galactosidase, from mice which had been injected with the RNA which codes for beta-galactosidase. To increase the efficiency of the RNA vaccine, the cytokine GM-CSF was additionally administered. This cytokine increases the efficiency of some DNA vaccines. It was furthermore found that the time of the GM-CSF injection influences the type of the immune response, compared with DNA injection (Kusakabe (2000) J. Immunol. 164: 3102-3111). It was found according to the invention that GM-CSF can enhance the immune response brought about by an RNA vaccination. The injection of GM-CSF one day before the injection of RNA shows scarcely any influence on the strength or the type of the immune response. In contrast, injection of GM-CSF 2 hours before injection of the RNA enhances the immune response (cf. the IL-4 release in fig. 3B in the 2 mice injected with GM-CSF at time $T = 0$), but does not influence

the Th2 polarity. On the other hand, if GM-CSF is injected one day after the RNA vaccine into the same site or into a site away from this (not shown), not only is the immune response enhanced overall (cf. the antibody response according to fig. 3), the immune response is polarized to the Th1 type (cf. the IFN-gamma production by splenocytes stimulated with beta-gal protein according to fig. 3A, the production of IgG2a antibodies against beta-Gal according to fig. 3B and the production of activated CTL according to fig. 1). The injection of GM-CSF some minutes or some hours after the RNA injection should result in the same effect (enhancement and polarization) on the immune response.

Example 3: Effect of an RNase inhibitor on mRNA expression
in vivo

Naked or protamine-associated or -complexed mRNA which codes for beta-galactosidase (prepared as described in example 2) was injected into the auricula of mice in an amount of 25 mg of RNA in injection buffer (150 mM NaCl, 10 mM HEPES). Further mice were injected with the mRNA which codes for beta-galactosidase, together with 10 U of the RNase inhibitor RNasin (an enzymatic RNase inhibitor extracted from the pancrease, obtainable from Roche or Promega). The RNase inhibitor was mixed with the RNA solution directly before the injection. After 12 hours, the ears were in each case removed from the mice. Thin microscope sections of the auriculae were prepared and were stained with X-gal. Injection of naked or protamine-associated mRNA leads to a detectable beta-galactosidase activity in a few cells in the corresponding thin sections (blue cells in fig. 5 and 6). Some cells have thus taken up

the exogenous RNA here and translated it into the protein. When the mRNA which codes for beta-galactosidase was in the form protected with the RNase inhibitor RNasin, very many more blue cells were observed than in the case of the naked
5 or protamine-associated RNA (fig. 7). Since RNasin inhibits RNases, the half-life of the injected mRNA molecules in vivo is prolonged, where the environment (interstitial tissue) is contaminated with RNases. Such a stabilization of the RNA leads to an increased uptake by the surrounding
10 cells and therefore to an increased expression of the protein coded by the exogenous RNA. This phenomenon can therefore also be utilized for an enhanced immune response to an antigen coded by the mRNA injected.

15 **Example 4: RNA vaccination of patients with malignant diseases**

Introduction

20 Cytotoxic T lymphocytes (CTL) recognize antigens as short peptides (8-9 amino acids) which are expressed bound to MHC class 1 glycoproteins on the cell surface (1). These peptides are fragments of intracellular protein molecules. However, there are indications that antigens taken up
25 exogenously by macropinocytosis or phagocytosis can lead to the CD8⁺ T cell-mediated immune response. The proteins are cleaved into proteosomes and the peptides formed by this means are transported out of the cytosol into the lumen of the endoplasmic reticulum and bound to MHC class I
30 molecules.

The proteins processed in this way are transported as peptide/MHC class I complex to the cell surface and presented to the CTL. This process takes place in every cell and in this way makes it possible for the immune system to monitor accurately each individual cell for the presence of proteins which are foreign to the body or modified or embryonic, regardless of whether they originate from intracellular pathogenic germs, oncogenes or dysregulated genes. By this means, cytotoxic lymphocytes are capable of recognizing and lysing infected and neoplastic cells, respectively (2, 3).

In recent years various tumour-associated antigens (TAA) and peptides which are recognized by CTL and therefore lead to lysis of tumour cells have been successfully isolated (21-27). These TAA are capable of stimulating T cells and inducing antigen-specific CTL, if they are expressed as a complex of HLA molecule and peptide on antigen-presenting cells (APC).

In numerous studies carried out mainly on patients with malignant melanoma, it has been possible to demonstrate that malignant cells lose the expression of TAA as the tumour disease proceeds. Similar circumstances are also observed with vaccinations with individual tumour antigens. Under vaccination therapies, selection of tumour cells may also occur, which renders possible an escape from the immune system and a progression of the disease in spite of therapy. The use of several different tumour antigens as envisaged in the treatment plan according to the invention of the present example should prevent selection of tumour

cells and escape of the malignant cells from the immune system due to loss of antigens.

A method with which DC can be transfected with RNA from a plasmid which codes for a tumour antigen has recently been developed (Nair et al., 1998, Nair et al., 2000). Transfection of DC with RNA for CEA or telomerase led to induction of antigen-specific CTL. This process renders it possible to induce CTL and T helper cells against several epitopes on various HLA molecules from a tumour antigen. A further advantage of this strategy is the fact that neither the characterization of the tumour antigens or epitopes used nor definition of the HLA haplotype of the patient is a prerequisite. By a polyvalent vaccine of this type, the probability of the occurrence of so-called clonal "tumour escape" phenomena could be reduced significantly. Furthermore, T cell-mediated immune responses against antigens processed and presented by the natural route and with possibly a higher immune dominance could be induced by this approach. By additional participation of MHC class II-restricted epitopes, the induced tumour-specific immune response could be enhanced and maintained for longer.

A treatment scheme according to the invention for tumour vaccination of patients with advanced malignant diseases (mammary, ovarian, colorectal, pancreatic and renal cell carcinomas) is provided by way of example. In this, RNA which has been prepared from plasmids which code for MUC1, Her-2/neu, telomerase and MAGE-1 tumour antigens and influenza matrix protein (IMP) (positive control) is administered intradermally to patients with the abovementioned malignant diseases. A CTL induction *in vivo*

is thereby rendered possible, in order to prevent the progression of the disease or to effect the regression thereof in this way. The tumour antigens mentioned are expressed on the malignant cells of mammary, ovarian,
5 colorectal, pancreatic and renal cell carcinomas.

According to the treatment plan (cf. the following statements in this respect and fig. 9), the RNA species prepared in the laboratory which code for CEA, MUC1,
10 Her-2/neu, telomerase, Mage-1 and IMP are administered to the patient i.d., initially 4 x on days 0, 14, 28 and 42. In addition, GM-CSF (Leucomax[®], 100 µg/m², Novartis/Essex Pharma) is administered s.c. to the patient in each case one day after the RNA inoculation.

15

The treatment according to the invention is an immunisation approach which requires only minimal interventions on the patient (injection). Therapy is conducted ambulant and is suitable for many tumour patients, without the limitation
20 to particular HLA types or defined T cell epitopes. Furthermore, polyclonal CD4⁺-T helpers and also CD8⁺-CTL can be induced by this therapy.

Treatment plan

25

The RNAs for several tumour antigens (MUC1, Her-2/neu, telomerase, MAGE-1) and for a control antigen, influenza matrix protein (IMP, a viral antigen) are administered i.d. to the patient on days 0, 14, 28 and 42. In addition, the
30 patients receive GM-CSF (Leucomax[®] (100 µg/m²) Novartis/Essex Pharma) s.c. in each case one day after the RNA inoculation. When the course of the disease is stable

or there is an objective tumour response (complete remission (CR) or partial remission (PR)), where appropriate the patients receive the vaccinations s.c. once a month. After the fourth injection (day 49), the response
5 of the tumour is evaluated radiologically, by laboratory chemistry and/or sonographically, and the immunological phenomena induced by the therapy are evaluated.

From day 70, the immunization therapy is continued at
10 intervals of 4 weeks.

On days 0, 14, 28, 42 and 49, in each case blood samples are taken for laboratory parameters, Diff-BB, FACS analysis and cytokines (50 ml in total). Restaging of the patients
15 takes place from day 49 and where appropriate every further 4 to 8 weeks.

The treatment plan is shown schematically in fig. 9.

20 Laboratory: clotting, electrolytes, LDH, β 2-M, CK, liver enzymes, bilirubin, creatinine, uric acid, total protein, CRP, tumour markers (Ca 12-5, Ca 15-3, CEA, Ca 19-9): 15 ml of blood.

Diff-BB: differential blood count with smear (5 ml of EDTA
25 blood).

Cytokines: 10 ml of serum

FACS: 10 ml of heparin blood.

ELIspot: 20 ml of heparin blood.

Multitest: analysis of the DTH reaction.

30 DTH: ("delayed type hypersensitivity", delayed T cell-mediated reaction) analysis of the reaction to intradermally administered RNA. In addition a skin

biopsy should be performed in the event of a positive DTH reaction (local anaesthesia is not necessary for this).

5 Preparation of RNA from plasmids

For production of a vaccine based on mRNA, only precursors which are chemically synthesized and purified from bacteria are required. This is preferably effected in a specially
10 equipped RNA production unit. This is in a sealed-off room which is declared an RNase-free zone, i.e. work with RNase (e.g. purification of plasmids) must not be carried out. Contamination with naturally occurring RNases is also constantly checked. This room is fitted out with new
15 apparatuses (4 °C and -20 °C refrigerators, heating block, sterile bench, centrifuges, pipettes) which have never been used for biological or clinical work. This RNA production unit is used exclusively for enzymatic production (*in vitro* transcription) of mRNA (without bacterial, viral or cell
20 culture work). The end product comprises a sterile RNA solution in HEPES/NaCl buffer. Quality analyses are carried out on a formaldehyde-agarose gel. In addition, the RNA concentration and the content of proteins are determined photometrically ($OD_{320} < 0.1$; ratio of $OD_{260}/OD_{280} > 1.8$ in
25 pure RNA). Possible contamination by LPS is analysed in the LAL test. All RNA samples are subjected to sterile filtration before administration.

Plasmid constructs

30

The chosen genes (CEA, mucin1, Her-2/neu, telomerase, Mage-A1 and influenza matrix) are amplified via a PCR using

a heat-stable high-performance enzyme (pfu, Stratagene). The genes originate from tumour cDNA (mucin1, Her-2/neu, telomerase), or they have been cloned into bacterial vectors (influenza matrix and MAGE-A1). The PCR fragments
5 are cleaved with restriction enzymes (mucin1: BglII-SpeI; Her-2/neu: HindIII-blunt-SpeI; telomerase: BglII-SpeI; MAGE-A1: BamHI-SpeI; influenza matrix protein: BglII-SpeI) and cloned into the T7TS-Plasmid (cf. fig. 8) via the BglII and SpeI restriction sites. Plasmids of high purity are
10 obtained via the Endo-free Maxiprep Kit (Qiagen, Hilden, Germany). The sequence of the vector is controlled via a double-strand sequencing from the T7 promoter up to the PstI site and documented. Plasmids with a correct inserted gene sequence without mutations are used for the
15 *in vitro* transcription. (Control via the published sequences: Accession Numbers: M11730 for Her-2/neu, NM_002456 for MUC1, NM_003219 for telomerase TERT, V01099 for influenza matrix and M77481 for MAGE-A1).

20 *in vitro* Transcription

Production of linear, protein-free DNA

500 µg of each plasmid are linearized in a volume of 0.8 ml
25 via digestion with the restriction enzyme PstI in a 2 ml Eppendorf reaction vessel. This cleaved construct is transferred into the RNA production unit. 1 ml of a mixture of phenol/chloroform/isoamyl alcohol is added to the linearized DNA. The reaction vessel is vortexed for
30 2 minutes and centrifuged at 15,000 rpm for 3 minutes. The aqueous phase is removed and mixed with 0.7 ml 2-propanol in a 2 ml reaction vessel. This vessel is centrifuged at

15,000 rpm for 15 minutes, the supernatant is discarded and 1 ml 75% ethanol is added. The reaction vessel is centrifuged at 15,000 rpm for 10 minutes and the ethanol is removed. The vessel is centrifuged for a further 2 minutes
5 and the residues of the ethanol are removed with a microlitre pipette tip. The DNA pellet is then dissolved in 1 µg/ml in RNase-free water.

Enzymatic synthesis of the RNA

10

The following reaction mixture is prepared in a 50 ml Falcon tube: 100 µg linearized protein-free DNA, 1 ml 5x buffer (200 mM Tris-HCl (pH 7.9), 30 mM MgCl₂, 10 mM spermidine, 50 mM NaCl, 50 mM DTT), 200 µl ribonuclease
15 (RNase) inhibitor (recombinant, 5,000 U), 1 ml rNTP mix (in each case 10 mM ATP, CTP, UTP; 2 mM GTP), 1 ml CAP analogue (8 mM), 150 µl T7 polymerase (3,000 U) and 2.55 ml RNase-free water. The total volume is 5 ml. The mixture is incubated at 37 °C for 2 hours in a heating block.
20 Thereafter, 100 U of RNase-free DNase are added and the mixture is incubated again at 37 °C for 30 minutes. The DNA matrix is enzymatically degraded by this procedure.

Description and origin of the individual components

25

T7 polymerase: purified from an *E. coli* strain which contains a plasmid with the gene for the polymerase. This RNA polymerase uses as the substrate only promoter sequences of the T7 phage; Fermentas.
30 NTPs: synthesized chemically and purified via HPLC. Purity more than 96 %; Fermentas.

CAP analogue: synthesized chemically and purified via HPLC. Purity more than 90 %; Institute of Organic Chemistry of the University of Tübingen.

RNase inhibitor: RNasin, for injection, prepared
5 recombinantly (*E. coli*); Promega.

DNase: Pulmozym[®] ("dornase alfa"); Roche

Purification

10 The RNA treated with DNase is mixed with 20 ml of a solution of 3.3 ml 5 M NH₄OAc plus 16.65 ml of ethanol. The mixture is incubated at -20 °C for 1 hour and centrifuged at 4,000 rpm for 1 hour. The supernatant is removed and the pellet is washed with 5 ml of 75 % RNase-free ethanol. The
15 vessel is centrifuged again at 4,000 rpm for 15 minutes and the supernatant is removed. The vessel is centrifuged again under the previous conditions and the ethanol which remains is removed with a microlitre pipette tip. The reaction vessel is opened and the pellet is dried under a sterile
20 bench in the sterile environment.

1 ml of RNase-free water is added to the dried RNA. The pellet is incubated at 4 °C for at least 4 hours. 2 µl of the aqueous solution are subjected to a quantitative
25 analysis (determination of the UV absorption at 260 nm). 2 ml of a phenol/chloroform/isoamyl alcohol solution are added to 1 ml of aqueous RNA solution. The mixture is vortexed for 2 minutes and centrifuged at 4,000 rpm for 2 minutes. The aqueous phase is removed with a microlitre
30 pipette and transferred into a new reaction vessel. 4 ml of a solution of 0.66 ml 5 M NH₄OAc plus 3.33 ml ethanol are added. The mixture is incubated at -20 °C for 1 hour and

- centrifuged at 4,000 rpm for 1 hour. The supernatant is removed and the pellet is washed with 75 % RNase-free ethanol. The vessel is centrifuged again at 4,000 rpm for 15 minutes and the supernatant is removed. The vessel is
- 5 centrifuged again under the previous conditions and the ethanol which remains is removed with a microlitre pipette tip. The reaction vessel is opened and the pellet is dried under a sterile bench in the sterile environment.
- 10 The RNA is dissolved in RNase-free water and adjusted to a concentration of 10 mg/ml. It is incubated for 12 hours at 4 °C. A final concentration of 2 mg/ml is achieved by addition of injection buffer (150 mM NaCl, 10 mM HEPES). The end product is preferably subjected to sterile
- 15 filtration under GMP conditions before use.

Application of the RNA

- Each patient receives at two different sites an intradermal
- 20 (i.d.) injection of in each case 150 µl of the injection solution in which in each case 100 µg of antigen-coding mRNA (CEA, Her-2/neu, MAGE-A1, mucin 1, telomerase, influenza matrix protein) are present in solution.
- 25 After the primary immunization, a booster immunization is carried out every 14 days, for the inoculations then to be repeated at a monthly interval. In each case one day after the RNA injection, GM-CSF (Leucomax[®], Sandoz/Essex Pharma) is administered subcutaneously (s.c.) to the patient.
- 30
- If a clinical response is present or the disease is stabilized, this therapy is continued at monthly intervals.

Further immunological investigations in vitro (optional)

Flow cytometry analyses of PBMC for quantification of CTL
5 precursors;

⁵¹Cr release tests;

Soluble receptor and cytokine levels in the serum;

DTH reaction (skin reaction to intradermally injected RNA,
"delayed type hypersensitivity", T lymphocyte-mediated
10 reaction); and

Skin biopsy samples from the injection site for
histological analysis for T cell infiltration (pathology).

Parameters for evaluation of the efficacy

15

To be able to answer the question of the efficacy of this
immunotherapy, the induction of tumour-specific T cells and
a measurable tumour remission is used. Parameters are
T cell reactions measured *in vitro* and *in vivo* and changes
20 in the size of bidimensionally recordable tumour
manifestation or laboratory chemistry parameters of the
course of the disease.

Objective remission is defined as the best response in the
25 form of a complete or partial remission, corresponding to
the criteria listed below. The remission rate is calculated
from the ratio of the number of patients with objective
remission and the total number of evaluable patients.

30 A change in the immune status, determined by immunotyping
of peripheral mononuclear cells, an increase in the
antigen-specific CTL precursor frequency in the peripheral

blood and the induction of a persistent tumour-specific
T cell activity are assessed as the immunological response
to the therapy. For this purpose, *in vitro* induction
cultures are established for activation of tumour-specific
5 CTL.

Remission criteria (acc. to UICC)

10 Complete remission (CR): Complete regression of all
measurable tumour manifestation,
documented by 2 control
investigations at least 4 weeks
apart.

15 Partial remission (PR): Decrease in size of the total
area dimensions (product of two
tumour diameters or linear
measurement of one-dimensionally
measurable lesions of all tumour
findings by 50 % for at least 4
20 weeks). No new occurrence of
tumour manifestations or
progression of a tumour finding.

"No Change" (NC): Decrease of all the measurable
tumour manifestations by less
25 than 50 % or increase in a tumour
finding.

Progression (PD): Increase in size of the tumour
parameters in at least one focus
or new occurrence of a tumour
30 manifestation.

References

1. Rammensee HG, Falk K, Rotzschke O: Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 11: 213, 1993.
2. Bevan M.J: Antigen presentation to cytotoxic T lymphocytes in vivo. J Exp Med 182: 639, 1995.
3. Rock K.L: A new foreign policy: MHC class I molecules police the outside world. Immunol Today 17:131, 1996.
4. Steinman, A.M: The dendritic cell system and its role in immunogenicity. Annu. Rev Immunol 9:271, 1991.
5. Steinman RM, Witmer-Pack M, Inaba K: Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 329:1, 1993.
6. Inaba K, Metlay JP, Crowley MT, Steinman RM: Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 172:631, 1990.
7. Austyn JM: New insight into the mobilisation and phagocytic activity of dendritic cells. J Exp Med 183:1287, 1996.
8. Romani N, Koide S, Crowley M, Witmer-Pack M, Livingstone AM, Fathman CG, Steinman RM: Presentation of exogenous protein antigens by dendritic cells to T cell clones. J Exp Med 169:1169, 1989.

9. Nair S, Zhou F, Reddy R, Huang L, Rouse BT: Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. *J Exp Med* 175:609, 1992.
10. Cohen PJ, Cohen PA, Rosenberg SA, Katz SI, Mule JJ: Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. *Eur J Immunol* 24:315, 1994.
11. Porgador A, Gilboa E: Bone-marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. *J Exp Med* 182:255, 1995.
12. Celluzzi CM, Mayordomo JI, Storkus WJ, M. T. Lotze MT, and L. D. Falo LD: Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. *J Exp Med* 183:283, 1996.
13. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. *J Exp Med* 183:87, 1996.
14. Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. *J Immunol* 156:2918, 1996.

15. Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. *J Exp Med* 183:317, 1996.

5

16. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ: Adenovirus mediated delivery of antigenic epitopes into DC by a means of CTL induction. *J Immunol* 158: 3270, 1997.

10

17. Fisch P, Köhler G, Garbe A, Herbst B, Wider D, Kohler H, Schaefer HE, Mertelsmann R, Brugger W, Kanz L: Generation of antigen-presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+hematopoietic progenitor cells in cancer patients. *Eur J Immunol* 26: 595, 1996.

15

18. Sallusto F, Cella M, Danieli C, Lanzavecchia A: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the Major Histocompatibility Complex class II compartment: Down regulation by cytokines and bacterial products. *J Exp Med* 182:389, 1995.

20

- 25 19. Bernhard H, Dysis ML, Heimfeld S, Hand S, Gralow JR, Cheever MA: Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. *Cancer Res* 55: 1099, 1995.

30

20. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engelman EG, Levy R: Vaccination of patients

with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52, 1996.

21. Robbins PF, Kawakami Y: Human tumor antigens recognized
5 by T cells. Curr Opin Immunol 8: 628, 1996.
22. Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO,
Eberlein TJ: Tumor-specific and HLA-A2 restricted
cytolysis by tumor-associated lymphocytes in human
10 metastatic breast cancer. J Immunol 155: 4486, 1995.
23. Peoples GE, Goedegebuure PS, Smith R, Linehan DC,
Yoshino I, Eberlein TJ: Breast and ovarian cancer
specific cytotoxic T lymphocytes recognize the same HER-
15 2/-neu derived peptide. Proc Natl Acad Sci USA 92: 432,
1995.
24. Fisk B, Blevins TL, Wharton JT, Ioannides CG:
Identification of an immunodominant peptide of HER-2/neu
20 protooncogene recognized by ovarian tumor-specific
cytotoxic t lymphocyte lines. J Exp Med 181: 2109, 1995.
25. Brossart P, Stuhler G, Flad T, Stevanovic S,
Rammensee H-G, Kanz L and Brugger W. HER-2/neu
25 derived peptides are tumor-associated antigens
expressed by human renal cell and colon carcinoma
lines and are recognized by in vitro induced
specific cytotoxic T lymphocytes. Cancer Res. 58:
732-736, 1998.

26. Apostolopoulos, V. and McKenzie, I. F. C., Cellular mucins: targets for immunotherapy. Crit. Rev. Immunol. 14: 293-302, 1995.
- 5 27. Brossart P, Heinrich KS, Stevanovic S, Stuhler G, Behnke L, Reichardt VL, Muhm A, Rammensee H-G, Kanz L, Brugger W. Identification of HLA-A2 restricted T cell epitopes derived from the MUC1 tumor antigen for broadly applicable cancer vaccines. Blood 93: 4309-4317, 1999
- 10 28. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of CTL responses in vivo after vaccinations with peptide pulsed dendritic cells. Blood 96:3102-8, 2000
- 15 29. Kugler A, Stuhler G, Walden P, Zöller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Müller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Müller GA, Ringert RH. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Med 3: 332-336, 2000 (IF 25,58)
- 20 30. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat.Med. 4:328
- 25 31. Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, Roder C, Haendle I, Leisgang W, Dunbar R, Cerundolo V, von Den DP, Knop J, Brocker EB, Enk A, Kampgen E, Schuler G (2000) Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible
- 30

in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J.Immunol. 165:3492

32. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi
5 P, Jonuleit H, Bender A, Maczek C, Schreiner D, von Den
DP, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G
(1999) Vaccination with mage-3A1 peptide-pulsed mature,
monocyte-derived dendritic cells expands specific
cytotoxic T cells and induces regression of some
10 metastases in advanced stage IV melanoma. J.Exp.Med.
190:1669

**Example 5: Vaccination with autologous, amplified tumour
RNA in patients with malignant melanoma**

15

Introduction

The incidence of malignant melanoma has increased sharply worldwide in recent years. If the melanoma disease is
20 already in the metastased stage at the time of diagnosis,
there is currently no therapy which has a positive
influence on the further course of the disease with
sufficient certainty.

25 Vaccination therapies carried out to date using dendritic
cells are very labour-, cost- and time-intensive because of
the complicated culturing of the cells (GMP conditions).
Furthermore, the studies have hitherto concentrated
predominantly on known tumour-associated antigens (TAA),
30 such as, for example, melan-A or tyrosinase.

A number of various immunological phenomena, such as, inter alia, the occurrence of spontaneous tumour regressions or spontaneous involution of metastases, have made the melanoma the prior candidate for testing immunotherapy investigations (Parkinson et al., 1992). In addition to experiments on non-specific stimulation of the immune system by means of interleukin-2, mistletoe extracts, BCG and interferons, which have so far not led to decisive breakthroughs in the therapy of advanced tumour diseases, the strategy of induction of various highly specific cytotoxic T lymphocytes (CTL) has been pursued in particular in recent years. These CTL are capable of recognizing and killing autologous melanoma cells (Boon et al., 1994; Houghton, 1994). Studies of this process have shown that the CTL recognize defined peptides in combination with MHC class I molecules. The presentation of peptides by antigen-presenting cells (APC) is the physiological route to generation of specific immune responses by lymphocytes (Rammensee, 1993). Dendritic cells have proved to be potent antigen-presenting cells which lead to an induction of the immune response by two routes: The first is the direct presentation of peptides towards CD8⁺-T lymphocytes and activation thereof (Schuler & Steinmann, 1985; Inaba et al., 1987; Romani et al., 1989), and the second is the generation of a protective immune response, which is mediated by CD4⁺ helper lymphocytes, and requires a presentation of peptides via MHC class II molecules (Grabbe et al., 1991, 1992, 1995).

By means of peptide analysis, it was therefore possible to identify in this way various tumour-associated antigens (TAA) which are specific for the melanoma and, after

presentation in combination with the MHC molecule and recognition by the CTL, lead to cytolysis of the tumour cells (Schadendorf et al., 1997, p. 21-27).

5 The use of autologous, dendritic cells was tested in the context of a pilot study on melanoma patients in respect of its potential to induce cytotoxic T lymphocytes effectively, rapidly and reliably. In this study, 16 melanoma patients in stage IV who had already been
10 pretreated by chemotherapy were vaccinated with peptide-charged dendritic cells. The response rates were above 30 % (5/16 patients) (Nestle et al., 1998). In a further independent study it was possible to demonstrate an even higher response rate of more than 50 % (6/11 patients)
15 after immunization of melanoma patients who had already been pretreated by chemotherapy with MAGE-3A1-charged dendritic cells (Thurner et al., 1999). A significant expansion of MAGE-A3-specific CD8⁺-T cells was also observed in 8/11 patients. A regression of the metastases took place
20 in some cases after the DC vaccination. This was accompanied by a CD8⁺-T cell infiltration. This showed that the T cells induced were active *in vivo*. A disadvantage of this strategy is the high outlay on costs and the laboratory (in particular GMP conditions). Large amounts of
25 blood from the patient are required for the time-intensive generation of the DC. In the preparation of the peptides, on the one hand only known tumour-associated antigens can be used, and on the other hand various peptides are necessary, depending on the HLA haplotype.

30

A further development of this approach is vaccination with RNA-transfected DC (Nair et al., 1998, Nair et al., 2000).

In the meantime, numerous studies demonstrate that DC from mice and humans which have been transfected with mRNA can induce an efficient CTL response *in vitro* and *in vivo* and can lead to a significant reduction in metastases

5 (Boczkowski et al., 1996, 2000; Ashley et al., 1997; Nair et al., 1998, 2000; Heiser et al., 2001; Mitchell and Nair, 2000; Koido et al., 2000; Schmitt et al., 2001). A great advantage in the use of RNA compared with peptides is that the most diverse peptides can be processed and presented

10 from one mRNA which codes for a TAA. By a polyvalent vaccine of this type, the probability of the occurrence of so-called clonal "tumour escape" phenomena can be reduced significantly. Furthermore, T cell-mediated immune responses against antigens processed and presented by the

15 natural route and with potentially a higher immune dominance can be induced by this system. By additional participation of MHC class II-restricted epitopes, the tumour-specific immune response induced can be intensified and maintained for longer. Nevertheless, this process also

20 can be carried out only with a high outlay on the laboratory (GMP conditions) because of the necessary culturing of the autologous DCs.

In the present strategy according to the invention,

25 vaccination is carried out with the RNA expression profile present in the autologous tumour of the patient. The specific tumour profile of the patient is thereby taken into account, unknown TAAs also being included in the inoculation. Expensive culture of the DCs is omitted, since

30 RNAs (not transfected DCs) are used in the vaccination.

A vaccination therapy using amplified autologous tumour RNA on patients with metastased malignant melanoma, in particular stage III/IV, is therefore provided according to the invention.

5

Tumour-specific cytotoxic T cells are induced *in vivo* by the vaccination, in order thus to achieve a clinico-therapeutic effect (tumour response). This is an immunisation system which requires only minimal

10 interventions on the patient (injection). Therapy can be conducted ambulant and is suitable for many tumour patients, without the limitation to particular HLA types or defined T cell epitopes. Furthermore, polyclonal CD4⁺-T helpers and also CD8⁺-CTL can be induced by this therapy.

15 From the point of view of the strategy, it is decisive also that hitherto unknown TAAs are taken into account in the vaccination protocol, and the exclusive use of autologous material is particularly advantageous.

20 Treatment plan

The amplified autologous tumour RNA is administered to the patient i.d. on days 0, 14, 28 and 42. In addition, the patients receive GM-CSF (Leucomax[®] 100 µg/m²,

25 Novartis/Essex) s.c. in each case one day after the RNA inoculation. Each patient receives, at two different sites, an i.d. injection of in each case 150 µl of the injection solution, in which in each case 100 µg of autologous tumour RNA is dissolved.

30

2 weeks after the fourth injection (day 56), where appropriate the response of the tumour is evaluated by a

staging analysis (inter alia sonography, thorax X-ray, CT etc.; in this context see the statements below) and by assessment of the immunological parameters induced by the therapy.

5

When the course of the disease is stable or there is an objective tumour response (CR or PR), the patients receive the vaccinations every four weeks. Further restaging analyses can be envisaged e.g. on day 126 and then at an interval of 12 weeks.

10

A diagram of the treatment plan is shown in fig. 13.

Preparation of autologous tumour RNA

15

The aim is the preparation of autologous poly(A⁺) RNA. For this, poly(A⁺) RNA is isolated from the patient's own tumour tissue. This RNA isolated is very unstable per se and its amount is limited. The genetic information is therefore transcribed into a considerably more stable cDNA library and thus conserved. Starting from the patient's own cDNA library, stabilized autologous RNA can be prepared for the entire treatment period. The procedure according to the invention is shown schematically in fig. 10.

20

25

Isolation of RNA

A process of Roche AG is used to isolate total RNA from a tumour tissue biopsy. The High Pure RNA Isolation Kit (order number 1828665) is employed here in accordance with the manufacturer's instructions. Poly(A⁺) RNA is isolated

30

from the total RNA via a further process of Roche AG with the High Pure RNA Tissue Kit (order number 2033674).

Preparation of a cDNA library

5

The cDNA library is constructed with the "SMART PCR cDNA Synthesis Kit" (Clontech Inc., USA; order number PT3041-1) in accordance with the manufacturer's instructions.

- 10 In this procedure, the single-stranded poly(A⁺) RNA is subjected to reverse transcription via a specific primer. Via a poly-C overhang at the 3'-end of the newly synthesized DNA, a further primer can hybridize, via which the construct can be amplified by a PCR. The double-
- 15 stranded cDNA fragments are now ready for cloning into a suitable RNA production vector (e.g. pT7TS; cf. fig. 8).

The process for the preparation of the cDNA library from the poly(A⁺) RNA with the aid of the above kit is shown

20 schematically in fig. 11.

Plasmid constructs

- The cDNA PCR fragments are cleaved with the restriction
- 25 enzymes NotI and SpeI and cloned into the corresponding restriction sites of the pT7TS vector by a procedure analogous to that described in example 4. Plasmids of high purity are obtained via the Endo-free Maxipreparation Kit (Qiagen, Hilden, Germany). Plasmids with a cloned-in gene
- 30 sequence which corresponds to the expected size fractionation (200 bp - 4,000 bp) of the cDNA library are used for the *in vitro* transcription. An example of a

separation of a representative cDNA library in an agarose gel is shown in fig. 12.

in vitro Transcription and RNA administration

5

The *in vitro* transcription and the administration of the RNA are carried out as described in the above example 4.

Investigations during the treatment

10

Before each inoculation (on the day of the inoculation):

Physical examination (including RR, fever);

Blood sample for routine laboratory values

1. Blood count, differential blood count: 3 ml

15 2. Electrolytes, LDH, CK, liver enzymes, bilirubin,
creatinine, uric acid, total protein, CRP: 5 ml

3. Blood sedimentation: 2 ml; and

at repeat inoculations additionally: Inspection of the injection sites.

20

On day 1 after each inoculation:

Physical examination (including RR, fever); and

Inspection of the injection sites.

25 In staging analyses on day 56 and 126 after the first inoculation, then every 12 weeks, additionally:

Extended routine blood sample:

1. Tumour marker S100 (7 ml)

2. Clotting values (3 ml);

30 Blood sample for immune monitoring (30 ml);

General well-being (ECOG score);

Imaging methods (thorax X-ray, sonography, skeleton scintigram, CT abdomen, pelvis, thorax, skull); and ECG ("EKG").

5 Further immunological investigations in vitro

Where appropriate, the relative incidence of antigen-specific CTL precursor cells in the peripheral blood of the patient in the course of time of the vaccination therapy is
10 measured.

On the one hand CTL precursor cells which are directed against antigens expressed to a particular degree by melanoma cells (tyrosinase, MAGE-3, melan-A, GP100) are
15 quantified here with FACS analyses (tetramer staining). On the other hand ELISpot analyses are carried out, these being designed such that CTL precursor cells which are directed specifically against hitherto unknown antigens are additionally recorded. For this, autologous dendritic cells
20 cultured from the peripheral blood of the patient are incubated with the same RNA with which the inoculation has also been carried out. These then serve as stimulator cells in the ELISpot analysis. The measurement thus records the total vaccine spectrum. For these analyses, blood samples
25 of 30 ml in total (20 ml ELISpot, 10 ml FACS analysis) can be envisaged for the immune monitoring in the context of the staging analyses and additionally on days 0, 14, 28 and 42, as well as a single withdrawal of 100 ml on day 70 for culture of the DC.

Furthermore, skin biopsy samples from the injection site can be obtained for histological analysis in respect of a T cell infiltration.

5 Parameters for evaluation of the efficacy

The efficacy of the therapy according to the invention is evaluated with the aid of the parameters described above in example 4.

10

References

- Anichini, A, Mortarini, R., Maccalli, C., Squarcina, P., Fleishhauer, K., Mascheroni, L., Parmiani, G. (1996).
15 Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J. Immunol. 156, 208-217.
- 20 Ashley, DM., Faiola, B., Nair, S., Hale, LP., Bigner, DD, Gilboa, E. (1997). Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce anti-tumor immunity against central nervous system tumors. J. Exp. Med. 186, 1177-1182.
- 25 Boczkowski, D., Nair, SK., Synder, D., Gilboa, E. (1996). Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472.
- 30 Boczkowski, D., Nair, SK., Nam, J., Lysterly, K., Gilboa, E. (2000). Induction of tumor immunity and cytotoxic T

lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60, 1028-1034.

- 5 Boon, T., Coulie, P., Marchand, M., Weynants, P., Wölfel, T., Brichard, V. (1994). Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. In Important Advances in Oncology 1994. DeVita, VT, Hellman, S., Rosenberg, SA, ed.
10 (Philadelphia: Lippincott Co), pp. 53-69.

- Garbe, C, Orfanos, CE (1989): Epidemiologie des malignen Melanoms in der Bundesrepublik Deutschland im internationalen Vergleich [Epidemiology of malignant
15 melanoma in the Federal Republic of Germany in an international comparison]. Onkologie 12, 253-262.

- Grabbe, S., Bruvers, S., Gallo, R.L., Knisely, T.L., Nazareno, R., and Granstein, R.D. (1991). Tumor antigen
20 presentation by murine epidermal cells. J Immunol. 146, 3656-3661.

- Grabbe, S., Bruvers, S., Lindgren, A.M., Hosoi, J., Tan, K.C., and Granstein, R.D. (1992). Tumor antigen
25 presentation by epidermal antigen-presenting cells in the mouse: modulation by granulocyte-macrophage colony-stimulating factor, tumor necrosis factor alpha, and ultraviolet radiation. J Leukoc.Biol. 52, 209-217.

- 30 Grabbe, S., Beissert, S., Schwarz, T., and Granstein, R.D. (1995). Dendritic cells as initiators of tumor immune

responses: a possible strategy for tumor
immunotherapy?. Immunol.Today 16, 117-121.

- 5 Heiser, A., Maurice, MA., Yancey, DR., Coleman, DM., Dahm,
P., Vieweg, J. (2001). Human dendritic cells
transfected with renal tumor RNA stimulate polyclonal T
cell responses against antigens expressed by primary
and metastatic tumors. Cancer Res. 61, 3388-3393.
- 10 Heiser, A., Maurice, MA., Yancey, DR., Wu, NZ., Dahm, P.,
Pruitt, SK., Boczkowski, D., Nair, SK., Ballo, MS.,
Gilboa, E., Vieweg, J. (2001). Induction of polyclonal
prostate cancer-specific CTL using dendritic cells
transfected with amplified tumor RNA. J. Immunol. 166,
15 2953-2960.
- Hoerr, I, Obst, R, Rammensee, HG, Jung, G (2000). In vivo
application of RNA leads to induction of specific
cytotoxic T lymphocytes and antibodies. Eur J Immunol.
20 30, 1-7.
- Houghton, AN (1994). Cancer antigens: immune recognition of
self and altered self. J.Exp.Med 180, 1-4

Inaba, K, Young, JW and Steinman, RM (1987). Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells. J.Exp.Med. 166, 182-194.

5 Koido, S., Kashiwaba, M., Chen, D., Gendler, S., Kufe, D., Gong, J. (2000). Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J. Immunol. 165, 5713-5719.

10 Mitchell, DA., Nair, SK. (2000). RNA-transfected dendritic cells in cancer immunotherapy. J. Clin. Invest. 106, 1065-1069.

Nair, S., Boczkowski, S., Synder, D., Gilboa, E. (1998).
15 Antigen presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur. J. Immunol. 27, 589-597.

Nair, S., Heiser, A., Boczkowski, D., Majumdar, A., Naoe, M.,
20 Lebkowski, JS., Vieweg, J., Gilboa, E. (2000). Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat. Med. 6, 1011-1017.

25

Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. (1998). Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat.Med 4, 328-332.

30

Parkinson, DR, Houghton, AN, Hersey, P, Borden, EC (1992). Biologic therapy for melanoma. I Cutaneous melanoma.

Balch, CM, Houghton, AN, Milton GW, Soober, AJ, Soong, SJ, ed. (Lippincott Co), pp. 522-541

Rammensee, H.G., Falk, K., and Rotzschke, O. (1993).

- 5 Peptides naturally presented by MHC class I molecules.
 Annu.Rev.Immunol. 11, 213-244.

Romani N, Koide S, Crowley M, Witmer-Pack M, Livingstone
 AM, Fathman CG, Steinman RM: Presentation of exogenous
 10 protein antigens by dendritic cells to T cell clones. J
 Exp Med 169:1169, 1989.

Schadendorf, D, Grabbe, S, Nestle, FO (1997). Vaccination
 with Dendritic Cells - A specific Immunomodulatory
 15 Approach. In Strategies for Immunointervention in
 Dermatology. Burg, G, Dummer, RG, ed. (Heidelberg, New
 York: Springer-Verlag),

Schmitt, WE., Stassar, MJJG., Schmitt, W., Littlee, M.,
 20 Cochlovius, B. (2001). In vitro induction of a bladder
 cancer-specific T-cell response by mRNA-transfected
 dendritic cells. J. Cancer Res. Clin. Oncol. 127, 203-
 206.

25 Schmoll HJ, Höffken K, Possinger K (1997): Kompendium
 Internistische Onkologie [Compendium of Internal
 Oncology], 2nd ed., Springer-Verlag Berlin, part 2,
 1415.

30 Schuler G and Steinmann RM (1985). Murine epidermal
 Langerhans cells mature into potent immunostimulatory
 dendritic cells in vitro. J.Exp.Med. 161, 526-546.

- Thurner, B., Haendle, I., Roder, C. et al. (1999).
Vaccination with Mage-3A1 peptide-pulsed mature,
monocyte-derived dendritic cells expands specific
5 cytotoxic T cells and induces regression of some
metastases in advanced stage IV melanoma. J. Exp. Med.
190, 1669-1678.

SEQUENCE LISTING

<110> CUREVAC GmbH

<120> STABILISED MRNA TUMOUR VACCINE

<130> 57945-NP

<140> CA 2,473,135

<141> 2002-12-19

<150> PCT/EP02/14577

<151> 2002-12-19

<150> DE 101 62 480.8

<151> 2001-12-19

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 45

<212> DNA

<213> Xenopus laevis

<220>

<223> Xenopus beta-Globin 5'-non-translatable region

<400> 1

gcttggttctt ttgacagaag ctcagaataa acgctcaact ttggc

45

<210> 2

<211> 157

<212> DNA

<213> Xenopus laevis

<220>

<223> Xenopus beta-Globin 3'-non-translatable region

<400> 2

gactgactag gatctgggta ccactaaacc agcctcaaga acacccgaat ggagtctcta 60
agctacataa taccaactta cacttacaaa atgttggtccc ccaaaatgta gccattcgta 120
tctgctccta ataaaaagaa agtttcttca cattcta 157

<210> 3

<211> 13

<212> RNA

<213> Artificial sequence

<220>

<223> Description of artificial sequence: Kozak-sequence

<400> 3

gccgccacca ugg

13

<210> 4
<211> 9
<212> PRT
<213> Artificial sequence

<220>
<223> Description of the artificial sequence: peptide for 51Cr-
release assay

<400> 4
Thr Pro His Pro Ala Arg Ile Gly Leu
1 5

<210> 5
<211> 15
<212> RNA
<213> Artificial sequence

<220>
<223> Description of artificial sequence: consensus sequence
contained in the 3'UTR of the very stable RNA encoding
alpha-Globin among others.

<220>
<223> Position 4: repeated x-times, Position 10: repeated x-times;
n = a or g or c or t/u unknown or other;

<400> 5
yccancccw ycycc

Claims:

1. A process for the preparation of a pharmaceutical composition comprising the steps:
 - (a) preparation of a part of a cDNA library from tumour tissue of a patient, wherein the part is a subtraction library of the entire cDNA library and codes for tumour-specific antigens, the sequences of the tumour specific antigens are determined before step (a) and wherein the determination of the sequences of the tumour-specific antigens comprises an alignment with a cDNA library from healthy tissue;
 - (b) preparation of a matrix for *in vitro* transcription of mRNAs with the aid of the part of the cDNA library; and
 - (c) *in vitro* transcribing of the matrix.
2. The process according to claim 1, wherein, for the pharmaceutical composition, the antigen(s) from a tumour is/are transcribed from the group consisting of 707-AP, AFP, ART-4, BAGE, β -catenin/m, Bcr-abl, CAMEL, CAP-1, CASP-8, CDC27/m, CDK4/m, CEA, CT, Cyp-B, DAM, ELF2M, ETV6-AML1, G250, GAGE, GnT-V, Gp100, HAGE, HER-2/neu, HLA-A*0201-R170I, HPV-E7, HSP70-2M, HAST-2, hTERT (or hTRT), iCE, KIAA0205, LAGE, LDLR/FUT, MAGE, MART-1/melan-A, MC1R, myosin/m, MUC1, MUM-1, -2, -3, NA88-A, NY-ESO-1, p190 minor bcr-abl, Pml/RAR α , PRAME, PSA, PSM, RAGE, RU1 or RU2, SAGE, SART-1 or SART-3, TEL/AML1, TPI/m, TRP-1, TRP-2, TRP-2/INT2 and WT1.

3. The process according to claim 1 or 2, wherein, in the pharmaceutical composition, the mRNA molecules are provided with at least one feature selected from the group consisting of: a 5' cap structure, a poly(A⁺) tail of at least about 25 nucleotides, at least one IRES, at least one 5'-stabilizing sequence, and at least one 3'-stabilizing sequence.
4. The process according to any one of claims 1 to 3, wherein one or more adjuvants are further added to the pharmaceutical composition.
5. The process according to claim 4, wherein the adjuvants added to the pharmaceutical composition are selected from the group consisting of: lipopolysaccharide, TNF- α , CD40 ligand, GP96, oligonucleotides with the CpG motif, aluminium hydroxide, Freund's adjuvant, lipopeptides and cytokines.
6. The process according to claim 5, wherein the cytokine GM-CSF is added to the pharmaceutical composition.
7. The process according to any one of claims 1 to 6, wherein, in the pharmaceutical composition, the mRNA molecules are complexed or condensed with at least one cationic or polycationic agent.
8. The process according to claim 7, wherein the cationic or polycationic agent is selected from the group consisting of protamine, poly-L-lysine, poly-L-arginine and histones.

9. The process according to any one of claims 1 to 8, wherein at least one RNase inhibitor is further added to the pharmaceutical composition.
10. The process according to claim 9, wherein the RNase inhibitor is RNasin.
11. The process according to any one of claims 1 to 10, wherein at least one further pharmaceutically acceptable carrier and/or at least one further pharmaceutically acceptable vehicle is added.
12. The process according to any one of claims 1 to 11, wherein the alignment comprises a comparison of the expression patterns of healthy and tumour tissue.
13. The process according to claim 12, wherein the determination of the sequences of the tumour-specific antigens comprises a diagnosis by a microarray.
14. The process according to claim 12 or 13, wherein the expression patterns are compared at the nucleic acid level.
15. The process according to claim 12, wherein the expression patterns are determined by expression analysis at the protein level.

Application number : numéro de demande: EP02/14577

Figures: 5, 6, 7, 12


Pages: _____

Unscannable items
received with this application
(Request original documents in File Prep. Section on the 10th floor)

Documents reçu avec cette demande ne pouvant être balayés
(Commander les documents originaux dans la section de préparation des dossiers au
10ème étage)

1/14


Fig. 1




3/14

Fig. 3

A




B




4/14

Fig. 4

A




B



8/14

Fig. 8

Xenopus β -globin 5' untranslated region


GCTTGTTCTTTTGCAGAAGCTCAGAATAAACGCTCAACTTTGGC

Xenopus β -globin 3' untranslated region

GACTGACTAGGATCTGGTTACCACTAAACCAGCCTCAAGAACACCCGA
 ATGGAGTCTCTAAGCTACATAATACCAACTTACACTTACAAAATGTTG
 TCCCCCAAATGTAGCCATTCGTATCTGCTCCTAATAAAAAGAAAGTT
 TCTTCACATTCTA


9/14

Fig. 9




10/14

Fig. 10



11/14

Fig. 11



13/14

Fig. 13

Day	-7	0	14	28	42	56	70	98	126	154	182	210
Week	-1	0	2	4	6	8	10	14	18	22	26	30
Inoculation		1	2	3	4	5	6	7	8	9	10	
GM-CSF sc		x	x	x	x	x	x	x	x	x	x	x
Blood sample	50	40	40	40	40	150	10	10	50	10	10	50
Staging	x					x			x			x

14/14

Fig. 14

